US20160096855A1 - Method of Treating Colorectal Cancer - Google Patents
Method of Treating Colorectal Cancer Download PDFInfo
- Publication number
- US20160096855A1 US20160096855A1 US14/943,859 US201514943859A US2016096855A1 US 20160096855 A1 US20160096855 A1 US 20160096855A1 US 201514943859 A US201514943859 A US 201514943859A US 2016096855 A1 US2016096855 A1 US 2016096855A1
- Authority
- US
- United States
- Prior art keywords
- cis
- group
- compound
- carbon atoms
- oxaliplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 58
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 241000124008 Mammalia Species 0.000 claims abstract description 31
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 100
- 229960001756 oxaliplatin Drugs 0.000 claims description 84
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 84
- 125000004432 carbon atom Chemical group C* 0.000 claims description 65
- 239000003446 ligand Substances 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 229910052697 platinum Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- -1 chloro, bromo, iodo Chemical group 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 13
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 12
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 12
- 229960002949 fluorouracil Drugs 0.000 claims description 12
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 11
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 11
- 235000008191 folinic acid Nutrition 0.000 claims description 11
- 239000011672 folinic acid Substances 0.000 claims description 11
- 229960001691 leucovorin Drugs 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 229940124647 MEK inhibitor Drugs 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 6
- FPJNQJHCHVUNTK-UHFFFAOYSA-N platinum;dihydrate Chemical compound O.O.[Pt] FPJNQJHCHVUNTK-UHFFFAOYSA-N 0.000 claims description 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 5
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960000397 bevacizumab Drugs 0.000 claims description 5
- 229960004117 capecitabine Drugs 0.000 claims description 5
- 229960005395 cetuximab Drugs 0.000 claims description 5
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims description 5
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 4
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 claims description 4
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 claims description 4
- HFPGRVHMFSJMOL-UHFFFAOYSA-N dibromomethane Chemical compound Br[CH]Br HFPGRVHMFSJMOL-UHFFFAOYSA-N 0.000 claims description 4
- ZJULYDCRWUEPTK-UHFFFAOYSA-N dichloromethyl Chemical compound Cl[CH]Cl ZJULYDCRWUEPTK-UHFFFAOYSA-N 0.000 claims description 4
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 150000003058 platinum compounds Chemical class 0.000 abstract description 3
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 76
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 59
- 229960004316 cisplatin Drugs 0.000 description 58
- 229940125904 compound 1 Drugs 0.000 description 47
- 206010028980 Neoplasm Diseases 0.000 description 34
- 229940079593 drug Drugs 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 239000000460 chlorine Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 229910019032 PtCl2 Inorganic materials 0.000 description 19
- 150000002431 hydrogen Chemical group 0.000 description 19
- 238000009472 formulation Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 0 [1*]C.[2*][Pt]1([3*])CC2*C(CC2)N1 Chemical compound [1*]C.[2*][Pt]1([3*])CC2*C(CC2)N1 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 15
- 229940125782 compound 2 Drugs 0.000 description 15
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000004700 cellular uptake Effects 0.000 description 11
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 206010034133 Pathogen resistance Diseases 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- IVFLQCDAHDZLBE-UHFFFAOYSA-N O=S(=O)=O.[H]C1=CC=C(OC)C(C(=O)OC)=C1 Chemical compound O=S(=O)=O.[H]C1=CC=C(OC)C(C(=O)OC)=C1 IVFLQCDAHDZLBE-UHFFFAOYSA-N 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- KIFHUHBBUBVJNH-UHFFFAOYSA-N COC(=O)C1(C(=O)OC)CCC1 Chemical compound COC(=O)C1(C(=O)OC)CCC1 KIFHUHBBUBVJNH-UHFFFAOYSA-N 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-YYWVXINBSA-N N,N-dimethylformamide-d7 Chemical compound [2H]C(=O)N(C([2H])([2H])[2H])C([2H])([2H])[2H] ZMXDDKWLCZADIW-YYWVXINBSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000004294 195Pt NMR spectroscopy Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 5
- 150000003057 platinum Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000020520 nucleotide-excision repair Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- YPXVIBPPGLUQPZ-UHFFFAOYSA-N COC(=O)C1(C(=O)OC)CCC1.O=S(=O)=O.[H]C1=CC=C(OC)C(C(=O)OC)=C1 Chemical compound COC(=O)C1(C(=O)OC)CCC1.O=S(=O)=O.[H]C1=CC=C(OC)C(C(=O)OC)=C1 YPXVIBPPGLUQPZ-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 102000011279 Multidrug resistance protein 1 Human genes 0.000 description 3
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000035567 cellular accumulation Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 2
- RQHMQURGSQBBJY-UHFFFAOYSA-N (2,2-dichloroacetyl) 2,2-dichloroacetate Chemical compound ClC(Cl)C(=O)OC(=O)C(Cl)Cl RQHMQURGSQBBJY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WYWICTDHAAMTQV-LPTUZNPKSA-J CC(=O)O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1 Chemical compound CC(=O)O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1 WYWICTDHAAMTQV-LPTUZNPKSA-J 0.000 description 2
- BULBBIKHHQIECW-UHFFFAOYSA-N COC(=O)C1(C(=O)OC)CO(C)C1 Chemical compound COC(=O)C1(C(=O)OC)CO(C)C1 BULBBIKHHQIECW-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 description 2
- 108020005124 DNA Adducts Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 2
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940120124 dichloroacetate Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZCOGQKZQCDIFKA-KQPWYKHGSA-A C.C=C1O[Pt]2(O)(O)(N[C@H]3CC[C@H](CC3)N2)OC1=O.CC(=O)O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1.C[Pt]1(O)(O)(Cl)N[C@H]2CC[C@H](CC2)N1.O=C1O[Pt]2(OC(=O)C(Cl)Cl)(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N2)OC1=O Chemical compound C.C=C1O[Pt]2(O)(O)(N[C@H]3CC[C@H](CC3)N2)OC1=O.CC(=O)O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1.C[Pt]1(O)(O)(Cl)N[C@H]2CC[C@H](CC2)N1.O=C1O[Pt]2(OC(=O)C(Cl)Cl)(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N2)OC1=O ZCOGQKZQCDIFKA-KQPWYKHGSA-A 0.000 description 1
- SYGHFPDTCRYDJR-RUTFAPCESA-L C=C1O[Pt]2(N[C@H]3CC[C@H](CC3)N2)OC1=O Chemical compound C=C1O[Pt]2(N[C@H]3CC[C@H](CC3)N2)OC1=O SYGHFPDTCRYDJR-RUTFAPCESA-L 0.000 description 1
- SUYOCUKUNAPWSE-LIAJSWTCSA-J C=C1O[Pt]2(O)(O)(N[C@H]3CC[C@H](CC3)N2)OC1=O Chemical compound C=C1O[Pt]2(O)(O)(N[C@H]3CC[C@H](CC3)N2)OC1=O SUYOCUKUNAPWSE-LIAJSWTCSA-J 0.000 description 1
- URJUVOHGDQASFT-LIAJSWTCSA-J C=C1O[Pt]2(OC(=O)C(Cl)Cl)(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N2)OC1=O Chemical compound C=C1O[Pt]2(OC(=O)C(Cl)Cl)(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N2)OC1=O URJUVOHGDQASFT-LIAJSWTCSA-J 0.000 description 1
- ASJADVYXEYCQPQ-MTYMQBKYSA-F CC(=O)O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1.O=C1O[Pt]2(OC(=O)C(Cl)Cl)(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N2)OC1=O Chemical compound CC(=O)O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1.O=C1O[Pt]2(OC(=O)C(Cl)Cl)(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N2)OC1=O ASJADVYXEYCQPQ-MTYMQBKYSA-F 0.000 description 1
- OXQZDWVPDVWPCD-LIAJSWTCSA-J CC(=O)O[Pt]12(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N1)OC(=O)C(=O)O2 Chemical compound CC(=O)O[Pt]12(OC(=O)C(Cl)Cl)(N[C@H]3CC[C@H](CC3)N1)OC(=O)C(=O)O2 OXQZDWVPDVWPCD-LIAJSWTCSA-J 0.000 description 1
- LNWKQCISRUYZSR-INHBEYBGSA-J CC(=O)O[Pt]12(OC(C)=O)(N[C@]3(C)C(C)(C)C(C)(C)[C@](C)(N1)C(C)(C)C3(C)C)OC(=O)C(=O)O2 Chemical compound CC(=O)O[Pt]12(OC(C)=O)(N[C@]3(C)C(C)(C)C(C)(C)[C@](C)(N1)C(C)(C)C3(C)C)OC(=O)C(=O)O2 LNWKQCISRUYZSR-INHBEYBGSA-J 0.000 description 1
- UZVWTMYNYRFSAN-OKZBWPRMSA-J CC1(C)C(C)(C)[C@]2(C)N[Pt](O)(O)(Cl)(Cl)N[C@@]1(C)C(C)(C)C2(C)C Chemical compound CC1(C)C(C)(C)[C@]2(C)N[Pt](O)(O)(Cl)(Cl)N[C@@]1(C)C(C)(C)C2(C)C UZVWTMYNYRFSAN-OKZBWPRMSA-J 0.000 description 1
- TYWOBSSXKOFDMI-INHBEYBGSA-J CC1(C)C(C)(C)[C@]2(C)N[Pt]3(O)(O)(N[C@@]1(C)C(C)(C)C2(C)C)OC(=O)C(=O)O3 Chemical compound CC1(C)C(C)(C)[C@]2(C)N[Pt]3(O)(O)(N[C@@]1(C)C(C)(C)C2(C)C)OC(=O)C(=O)O3 TYWOBSSXKOFDMI-INHBEYBGSA-J 0.000 description 1
- FAQYXVAWUZWXQX-UHFFFAOYSA-N COC1(C[N]2(CC2)C1)OC Chemical compound COC1(C[N]2(CC2)C1)OC FAQYXVAWUZWXQX-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N COc(ccc(N)c1)c1OC Chemical compound COc(ccc(N)c1)c1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- AJGQYPPGUZWMLQ-UHFFFAOYSA-M C[Pt]1(Cl)NC2CCC(CC2)N1 Chemical compound C[Pt]1(Cl)NC2CCC(CC2)N1 AJGQYPPGUZWMLQ-UHFFFAOYSA-M 0.000 description 1
- MQHBBUYCLKBAII-LPTUZNPKSA-K C[Pt]1(O)(O)(Cl)N[C@H]2CC[C@H](CC2)N1 Chemical compound C[Pt]1(O)(O)(Cl)N[C@H]2CC[C@H](CC2)N1 MQHBBUYCLKBAII-LPTUZNPKSA-K 0.000 description 1
- 101100317273 Caenorhabditis elegans ddl-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HQELQGXPKPESMW-UHFFFAOYSA-L Cl[Pt]1(Cl)NC2CCC(CC2)N1 Chemical compound Cl[Pt]1(Cl)NC2CCC(CC2)N1 HQELQGXPKPESMW-UHFFFAOYSA-L 0.000 description 1
- UUERTZXRKZEANK-SKSSAGQDSA-L Cl[Pt]1(Cl)N[C@@H]2CCCC[C@H]2N1 Chemical compound Cl[Pt]1(Cl)N[C@@H]2CCCC[C@H]2N1 UUERTZXRKZEANK-SKSSAGQDSA-L 0.000 description 1
- 102100036576 Coiled-coil domain-containing protein 174 Human genes 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 108010093204 DNA polymerase theta Proteins 0.000 description 1
- 102100029766 DNA polymerase theta Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101710196315 High affinity copper uptake protein 1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910020427 K2PtCl4 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- RTDASODMQURLMN-LPTUZNPKSA-J O=C(O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1)C(Cl)Cl Chemical compound O=C(O[Pt]1(Cl)(Cl)(OC(=O)C(Cl)Cl)N[C@H]2CC[C@H](CC2)N1)C(Cl)Cl RTDASODMQURLMN-LPTUZNPKSA-J 0.000 description 1
- JVRFNAYJSUMVKZ-UHFFFAOYSA-L O=C1O[Pt]2(NC3CCC(CC3)N2)OC(=O)C12CCC2 Chemical compound O=C1O[Pt]2(NC3CCC(CC3)N2)OC(=O)C12CCC2 JVRFNAYJSUMVKZ-UHFFFAOYSA-L 0.000 description 1
- MLGUEVQSYYXGFD-RUTFAPCESA-L O=C1O[Pt]2(N[C@H]3CC[C@H](CC3)N2)OC1=O Chemical compound O=C1O[Pt]2(N[C@H]3CC[C@H](CC3)N2)OC1=O MLGUEVQSYYXGFD-RUTFAPCESA-L 0.000 description 1
- RXGZKCNJDORCTO-UHFFFAOYSA-N O=S(=O)=O.[H]C1=CC=C(OC)C(CC)=C1 Chemical compound O=S(=O)=O.[H]C1=CC=C(OC)C(CC)=C1 RXGZKCNJDORCTO-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229910019029 PtCl4 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 1
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000009838 combustion analysis Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SAUMVKNLVQDHMJ-UHFFFAOYSA-N dichlorine trioxide Inorganic materials ClOCl(=O)=O SAUMVKNLVQDHMJ-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910001385 heavy metal Chemical class 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002436 one-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical class [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000005610 quantum mechanics Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- FBEIPJNQGITEBL-UHFFFAOYSA-J tetrachloroplatinum Chemical compound Cl[Pt](Cl)(Cl)Cl FBEIPJNQGITEBL-UHFFFAOYSA-J 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention relates to the use of certain platinum compounds or combinations of these compounds with a variety of other therapeutic agents for treating and/or preventing the progression of colorectal cancer in mammals.
- the invention provides methods of treating and/or preventing oxaliplatin-refractory colorectal cancer in mammals.
- Platinum drugs cisplatin, cis-diamminedichloroplatinum(II), CDDP; carboplatin, diammine[1,1-cyclobutanedicarboxylato]platinum(II); and oxaliplatin, [(1R,2R)-cyclohexane-1,2 diamine](ethanedioato)platinum(II); FIG. 1 ) are widely used in the clinic and the prototype cisplatin still represents an antineoplastic drug with highly curative effects in a solid malignancy such as testicular cancer ( Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug . (Lippert, B., Eds.).
- the complex [PtCl 2 (cis-1,4-DACH)] (DACH diaminocyclohexane), [SP-4-2-(cis)]-dichloro(1,4-cyclohexanediamine-N,N′)platinum, compound 1 ( FIG. 1 ), contains an isomeric form of the diaminocyclohexane ligand found in oxaliplatin and has been widely investigated as a potential new platinum anticancer drug.
- Compound 1 also called “Kiteplatin” based on its structural features (Ranaldo, R., et al., Inorg. Chem.
- compound 1 proved to be more dose potent than cisplatin (based on % T/C values) against the parental L1210 and P388 murine leukemias.
- Compound 1 also retained a significant activity against sublines derived from L1210 and P388 and made resistant to cisplatin. Both compound 1 and cisplatin produced equivalent activity against B16 melanoma and M5076 sarcoma, while cisplatin was more active than compound 1 against colon carcinoma 26 at equitoxic doses.
- a peculiar feature of platinum-coordinated cis-1,4-DACH is the formation of a seven-membered chelate ring, which is larger than the usually encountered five- and six-membered rings (X-ray diffraction data) (Hoeschele, J. D., et al, J. Med. Chem. 1994, 37, 2630-2636 and Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830). This results in a very large bite angle ( ⁇ 97°) that could affect mobility of cis ligands.
- compound 1 The unique antitumor activity of compound 1 was further investigated with reference to: cell entry, reaction with sulfur-containing compounds, binding to DNA, and processing of DNA adducts by proteins (including DNA repair enzymes) (Kasparkova, J., et al., Biochem. Pharmacol. 2010, 79, 552-564).
- compound 1 revealed: i) improved cytotoxicity (3.4-5.4-fold greater) and enhanced cellular uptake (ca.
- Colorectal cancer is at the top of the list of the most common cancers worldwide, with around 1 million new cases diagnosed every year (Van Cutsem, E., et al., J. Clin. Oncol. 2007, 25, 1658-1664). Early stage colorectal cancer is frequently curable with surgery, but the appearance of metastases leads to unresectable tissues with fatal consequences for the patient (Saltz, L. B., et al., J. Clin. Oncol. 2004, 22, 1201-1208). The best outcome in the therapy of metastatic colorectal cancer is obtained by the use of 5-fluorouracil, oxaliplatin, and irinotecan. More recently, biologic therapies have also proved to be effective in prolonging the median survival time (Sobrero, A. F., et al., J. Clin. Oncol. 2008, 26, 2311-2319).
- the present invention answers the need by providing compounds of formula I and formula II and in particular compound 1. Therefore, compound 1 was evaluated against human colorectal cancer cells and, in particular, colorectal cancer cells resistant to oxaliplatin (Margiotta, N., et al., J. Med. Chem. 2012, 55(16), pp 7182-7192). We surprisingly and unexpectedly found that compounds of formula I and formula II and in particular compound 1 was effective in treating refractory colorectal cancer and especially in circumventing cisplatin and oxaliplatin resistance in colorectal cancer.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I
- R is —(CH 2 ) n — in which n is an integer from one to three;
- R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl;
- R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxala
- R 4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms
- R is —(CH 2 ) n —, in which n is an integer from two to three; R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms or an alkoxy group of from one to four carbon atoms; and R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro and bromo or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of
- R 1 is hydrogen, carboxyl, methyl, or methoxy.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of compound of formula I
- R is —(CH 2 ) n — in which n is an integer from one to three;
- R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl;
- R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxala
- R 4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I
- R is —(CH 2 ) n — in which n is an integer from one to three;
- R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl;
- R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxala
- R 4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms
- At least one second therapeutic agent useful in treating colorectal cancer selected from the group consisting of: capecitabine; cetuximab; bevacizumab; a MEK inhibitor; a FOLFOX4 dosing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin; and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I and a MEK inhibitor which is N—[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
- R is —(CH 2 ) n — in which n is an integer from one to three;
- R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl;
- R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxala
- R 4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms
- a second therapeutic agent useful in treating colorectal cancer selected from the group consisting of: capecitabine, cetuximab, bevacizumab, a MEK inhibitor, a FOLFOX4 dosing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin and at least one carrier, diluent or excipient.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula II
- R is —(CH 2 ) n — in which n is an integer from one to three;
- R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl;
- R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxala
- R 4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms
- R 5 and R 6 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, benzoato, 3,4,5-trihydroxybenzoato, 3,4,5-trimethoxybenzoato, R 7 (CH 2 ) p —CO 2 — wherein R 7 is selected from the group consisting of methyl, trifluoromethyl, CH 2 Cl, CH 2 Br, CH 2 F, CHCl 2 , CHBr 2 and CHF 2 and p is zero or an integer of one to five and R 7 (CH 2 ) q —O— wherein R 7 is defined above and q is zero or an integer of one to five.
- R is —(CH 2 ) n —, in which n is an integer from two to three; R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms or an alkoxy group of from one to four carbon atoms; and R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro and bromo or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of
- R 1 is hydrogen, carboxyl, methyl, or methoxy.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula II
- R is —(CH 2 ) n — in which n is an integer from one to three;
- R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl;
- R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, and acetato and dichloroacetato or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxal
- R 4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms
- R 5 and R 6 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, benzoato, 3,4,5-trihydroxybenzoato, 3,4,5-trimethoxybenzoato, R 7 (CH 2 ) p —CO 2 — wherein R 7 is selected from the group consisting of methyl, trifluoromethyl, CH 2 Cl, CH 2 Br, CH 2 F, CHCl 2 , CHBr 2 and CHF 2 and p is zero or an integer of one to five and R 7 (CH 2 ) q —O— wherein R 7 is defined above and q is zero or an integer of one to five and at least one carrier, diluent or excipient.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula II
- R is —(CH 2 ) n — in which n is an integer from one to three;
- R 1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl;
- R 2 and R 3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, nitrato, nitrito, acetato and dichloroacetato or R 2 and R 3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato,
- R 4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms
- R 5 and R 6 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, benzoato, 3,4,5-trihydroxybenzoato, 3,4,5-trimethoxybenzoato, R 7 (CH 2 ) p —CO 2 — wherein R 7 is selected from the group consisting of methyl, trifluoromethyl, CH 2 Cl, CH 2 Br, CH 2 F, CHCl 2 , CHBr 2 and CHF 2 and p is zero or an integer of one to five and R 7 (CH 2 ) q —O— wherein R 7 is defined above and q is zero or an integer of one to five and at least one second therapeutic agent useful in treating colorectal cancer selected from the group consisting of: capecitabine; cetuximab; bevacizumab; a MEK inhibitor; a FOLFOX4 dosing schedule consisting
- the refractory colorectal cancer is oxaliplatin-refractory colorectal cancer.
- the present invention is directed to treating a human.
- Another embodiment of the present invention is a compound having the following structure
- Another embodiment of the present invention is a compound having the following structure
- FIG. 1 Structures of Cisplatin, Carboplatin, Oxaliplatin, [PtCl 2 (1R,2R-DACH)] (Compound 2), and [PtCl 2 (cis-1,4-DACH)] (Compound 1).
- FIG. 2 Intracellular accumulation of platinum complexes detected by GF-AAS analysis. LoVo (panel A) and LoVo-OXP (panel B) cells were incubated with 5 ⁇ M of compound 1, compound 2, and oxaliplatin (OXP) for 6, 24, and 48 h. Error bars indicate standard deviation. *p ⁇ 0.05 and **p ⁇ 0.01 compared to control, °p ⁇ 0.05 compared to oxaliplatin treated cells.
- FIG. 3 The body weight changes of LLC-bearing C57BL mice treated with vehicle or tested compounds. Each drug was administered daily from day 9 and the weights were detected at day 1 and daily from day 9. The error bars indicate the S.D.
- FIG. 4 In vivo anticancer activity against LoVo and LoVo-OXP xenograft models.
- BALB/C nude mice bearing established human LoVo and LoVo OXP colorectal adenocarcinoma xenografts were daily ip dosed with either vehicle (Ctr) 0.9% NaCl, 1 at 3 mg/kg or OXP at 2 mg/kg from day 14 to day 30.
- the error bars indicate the SD.
- FIG. 5 Body weight changes. The body weight changes of LoVo (panel A) and LoVo-OXP (panel B) xenograft mice treated with vehicle (Ctr) or tested compounds. Body weight was daily measured, from day 14 to day 30, and was taken as a parameter of systemic toxicity. The error bars indicate the SD.
- alkyl means a straight or branched chain hydrocarbon group having from one to ten carbon atoms and includes for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, nonyl, and the like.
- Alkoxy is O-alkyl in which alkyl is as defined above.
- Cycloalkyl means a saturated hydrocarbon ring having three to six carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- Hydroalkyl means a hydroxy group attached to an alkyl radical in which alkyl is as defined above.
- Halogen is iodine, bromine, fluorine and chlorine.
- mice refers to mice, rats, rabbits, guinea pigs, sheep, goats, cats, dogs, monkeys etc.
- mouse refers to humans.
- treating refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition such as colorectal cancer.
- treating refers to having a therapeutic effect in refractory colorectal cancer and more preferably “treating” oxaliplatin-refractory colorectal cancer.
- preventing refers to decreasing the probability that a mammal including a human contracts or develops colorectal cancer.
- preventing refers to decreasing the probability that a mammal including a human contracts or develops refractory colorectal cancer and more preferably “preventing” oxaliplatin-refractory colorectal cancer.
- refractory colorectal cancer refers to a mammal including a human who is either initially unresponsive to therapy or who becomes unresponsive to therapy over time.
- oxaliplatin-refractory colorectal cancer refers to a mammal including a human who failed to respond to oxaliplatin-based therapy or whose disease has progressed after such treatment.
- the neutral mixed ligand platinum complexes/compounds of formula I and formula II are restricted to the cis-geometric isomers. Complexes of formula I and formula II may also possess asymmetric carbon atoms (chiral centers) and thus the racemates, individual enantiomer as well as mixtures of enantiomers are also included within the scope of the invention.
- the compounds of the invention may exist in both unsolvated and solvated forms.
- solvate is used herein to describe a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- hydrate is employed when the solvent is water.
- Pharmaceutically acceptable solvates in accordance with the invention include hydrates and solvates wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, d 6 -DMSO.
- the invention also includes isotopically-labeled compounds, which are identical to a compound of formula I or formula II, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, chlorine and platinum such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 36 Cl, 191 Pt and 195m PT respectively.
- Compounds of the present invention which contain the aforementioned isotopes and/or other isotopes of other atoms, are within the scope of this invention.
- Certain isotopically-labeled compounds of the present invention are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
- An isotopically labeled compound of formula I or II of the invention can generally be prepared by carrying out the procedures described for the non-labeled compounds, substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts.
- complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts.
- the resulting complexes may be ionized, partially ionized, or non-ionized.
- Compounds of Formula I and Formula II may be prepared according to the procedures described in the literature. See for example U.S. Pat. No. 4,999,444; Hoeschele, J., et al., J. Med. Chem. 1994, 37, 2630-2636; Shamsuddin, S., Inorg. Biochem. 1996, 61, 291-301; Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830; Dhara, S. C., Indian J. Chem. 1970, 8, 193-194; and Shamsuddin, S., J. Inorg. Biochem. 1998, 71, 29-35.
- the present invention also provides combinations, methods of using combinations and kits for use in combination therapies, using a compound of formula I or formula II and a variety of other therapeutic agents.
- the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I or II and at least one second therapeutic agent useful in treating colorectal cancer.
- the second therapeutic agent may be selected from the group consisting of: capecitabine; cetuximab; bevacizumab; a MEK inhibitor such as N—[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, or a pharmaceutically acceptable salt thereof; a FOLFOX4 doing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin; and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin and the like.
- Effective dosages of a second therapeutic agent(s) would be known to one skilled in the art (see for example Physicians' Desk Reference 67 th ed. 2013) and if needed may be further varied at the discretion of the prescribing physician.
- the compounds of the present invention may be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
- Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be used as fillers in soft or hard capsules and typically include a pharmaceutically acceptable carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- a pharmaceutically acceptable carrier for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil
- emulsifying agents and/or suspending agents may also be prepared by the reconstitution of a solid, for example, from a sachet.
- the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang, A. C. and Chen, L. H., Expert Opinion on Therapeutic Patents, 2001, 11 (6), 981-986, the disclosure of which is incorporated herein by reference in its entirety.
- the drug may make up from 1 wt % to 80 wt % of the dosage form, more typically from 5 wt % to 60 wt % of the dosage form.
- tablets generally contain a disintegrant.
- disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate.
- the disintegrant will comprise from 1 wt % to 25 wt %, preferably from 5 wt % to 20 wt % of the dosage form.
- Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose.
- Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
- diluents such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
- Tablets may also optionally include surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
- surface active agents such as sodium lauryl sulfate and polysorbate 80
- glidants such as silicon dioxide and talc.
- surface active agents are typically in amounts of from 0.2 wt % to 5 wt % of the tablet, and glidants typically from 0.2 wt % to 1 wt % of the tablet.
- Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
- Lubricants generally are present in amounts from 0.25 wt % to 10 wt %, preferably from 0.5 wt % to 3 wt % of the tablet.
- compositions include anti-oxidants, colorants, flavoring agents, preservatives and taste-masking agents.
- Exemplary tablets contain up to about 80 wt % drug, from about 10 wt % to about 90 wt % binder, from about 0 wt % to about 85 wt % diluent, from about 2 wt % to about 10 wt % disintegrant, and from about 0.25 wt % to about 10 wt % lubricant.
- Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tableting.
- the final formulation may include one or more layers and may be coated or uncoated; or encapsulated.
- Solid formulations for oral administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- Suitable modified release formulations are described for example in U.S. Pat. No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles can be found, for example in Verma, R. K. and Garg, S., Pharmaceutical Technology On - line, 2001, 25(2), 1-14. The use of chewing gum to achieve controlled release for example is described in WO 00/35298. The disclosures of these references are incorporated herein by reference in their entireties.
- the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
- Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
- Suitable devices for parenteral administration include needle (including micro needle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9)
- a suitable vehicle such as sterile, pyrogen-free water.
- parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
- Formulations for parenteral administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound.
- examples of such formulations include drug-coated stents and poly lactic-co-glycolic acid (PLGA) microspheres.
- the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
- Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used.
- Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
- Penetration enhancers may be incorporated; see, for example, Finnin, B. C. and Morgan, T.
- Formulations for topical administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- Compounds of the invention may also be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
- Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
- soluble macromolecular entities such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers
- Drug-cyclodextrin complexes are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used.
- the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubilizer. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in PCT Publication Nos. WO 91/11172, WO 94/02518 and WO 98/55148, the disclosures of which are incorporated herein by reference in their entireties.
- an effective dosage is typically in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 0.01 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.07 to about 7000 mg/day, preferably about 0.7 to about 2500 mg/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be used without causing any harmful side effect, with such larger doses typically divided into several smaller doses for administration throughout the day.
- kits suitable for coadministration of the compositions may conveniently be combined in the form of a kit suitable for coadministration of the compositions.
- the kit of the invention includes two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
- An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
- the kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
- the kit typically includes directions for administration and may be provided with a memory aid.
- the compounds of formula I and II are valuable anticancer agents.
- the anticancer activity of representative compounds of formula I and II were compared to other known anticancer platinum compounds in various in vitro and in vivo assays.
- MCF-7 and colon (HCT-15, DDL1, SW480 and CaCo-2) carcinoma cell lines along with melanoma (A375) were obtained from the American Type Culture Collection (ATCC, Rockville, Md.).
- A431 are human cervical carcinoma cells kindly provided by Prof F Zunino (Molecular Pharmacology Unit, Experimental Oncology and Molecular Medicine, Istituto Nazionale dei Tumori, Milan, Italy).
- 2008 and its cisplatin resistant variant, C13* are human ovarian cancer cell lines kindly provided by Prof. G. Marverti (Dept. of Biomedical Science, University of Modena, Italy).
- LoVo human colon-carcinoma cell line and its multidrug-resistant sublime were kindly provided by Prof. F. Maj one (Department of Biology of Padova University, Italy).
- the LoVo-OXP cells were derived using a standard protocol in which LoVo cells were grown in increasing concentrations of oxaliplatin and resistant clones were selected over a period of nine months (Gandin, V., et al., J. Cell. Mol. Med. 2012, 16, 142-151). Cell lines were maintained in the logarithmic phase at 37° C.
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- 3-8 ⁇ 10 3 cells well ⁇ 1 were seeded in 96-well microplates in growth medium (100 ⁇ L) and then incubated at 37° C. in a 5% carbon dioxide atmosphere. After 24 h, the medium was removed and replaced with a fresh one containing the compound to be studied, at the appropriate concentration, dissolved in 0.9% sodium chloride solution just before use. Triplicate cultures were established for each treatment. After 72 h, each well was treated with 10 mL of a 5 mg mL ⁇ 1 MTT saline solution and, after 5 h of incubation, 100 ⁇ L of a sodium dodecylsulfate (SDS) solution in 0.01 M HCl were added.
- SDS sodium dodecylsulfate
- IC 50 values represent the drug concentrations that reduce the mean absorbance at 570 nm to 50% of those in the untreated control wells.
- Compound 1 was prepared for the first time almost twenty years ago however, until now, it had been tested (both in vitro and in vivo) only in a limited number of tumor cell lines (Hoeschele, J. D., et al., J. Med. Chem. 1994, 37, 2630-2636 and Shamsuddin, S., et al., J. Inorg. Biochem. 1996, 61, 291-301).
- cytotoxicity was evaluated by means of the MTT test for 72 h treatment with increasing concentrations of the tested compounds.
- cytotoxicity of cisplatin, the most widely used anticancer metallodrug, and oxaliplatin, key drug in FOLFOX (Folinic acid, 5-Fluorouracil & Oxaliplatin) regimens for the treatment of colorectal cancers were evaluated in the same experimental conditions.
- IC 50 values calculated from dose-survival curves, are shown in Table 1.
- Compound 1 was found, on average, slightly more effective than oxaliplatin, much more effective than cisplatin (by a factor of 3-6) in two out of the seven cell lines particularly in HCT-15 and CaCo-2 cells characterized for their scarce sensitivity to cisplatin, and, on the average, 2-4 times more active than compound 2, which has the same diamine of oxaliplatin but chloride leaving ligands like compound 1.
- Compound 3 elicited an average cytotoxic activity lower than that of oxaliplatin and comparable to that of compound 2 and cisplatin, being, however, 3 times more effective than cisplatin against CaCo-2 colon cancer cells.
- Compound 4 possessed an average cytotoxic potency lower than oxaliplatin but slightly higher than cisplatin, with IC 50 values in five out of the seven cell lines up to 2-fold lower than that of cisplatin.
- Compound 5 was found to possess, on average, a cytotoxic activity rather similar to oxaliplatin and roughly 3 times better than cisplatin and compound 2.
- Compound 8 elicited an average cytotoxic activity lower than that of oxaliplatin and comparable to that of cisplatin.
- the eight compounds were additionally tested for their in vitro antitumor activity in two pairs of human cell lines which were selected for their resistance to cisplatin (ovarian cancer cells 2008/C13*), or oxaliplatin (colon cancer cells LoVo/LoVo-OXP).
- a LoVo cell line retaining a multidrug resistance phenotype was also considered (LoVo MDR).
- Cross-resistance profiles were evaluated by means of the resistance factor (RF), which is defined as the ratio between the IC 50 value for the resistant cells and that arising from the sensitive cells (Table 2).
- RF resistance factor
- b 1 [PtCl 2 (cis-1,4-DACH)] 2: [PtCl 2 (1R,2R-DACH)] 3: [Pt(OXA)(cis-1,4-DACH)] 4: cis,trans,cis-[Pt IV Cl 2 (OH) 2 (cis-1,4-DACH)] 5: cis,trans,cis-[Pt IV Cl 2 (DCA) 2 (cis-1,4-DACH)] 6: [Pt(CBDCA)(cis-1,4-DACH)] 7: cis,trans,cis-[Pt IV (OXA)(OH) 2 (cis-1,4-DACH)] 8: cis,trans,cis-[Pt IV (OXA)(OH) 2 (cis-1,4-DACH)] 8: cis,trans,cis-[Pt IV (OXA)(OH) 2 (cis-1,4-DACH)] 8: c
- Cisplatin resistance is multifactorial in nature, however the main molecular mechanisms involved in drug resistance of C13* cancer cells have been identified in high cellular glutathione and thioredoxin reductase levels, in reduced cellular drug uptake, and in enhanced repair of DNA damage.
- oxaliplatin induces the same type of DNA crosslinks as cisplatin, it is effective also in cell lines resistant to cisplatin, thus suggesting that the two complexes may have different mechanism of resistance (Gatti, L.; Perego, P. Cellular resistance to oxaliplatin and drug accumulation defects. In: Bonetti, A. et al., editors. Cancer drug discovery and development platinum and other heavy metal compounds in cancer chemotherapy. New York: Humana Press; 2009. p. 115-124).
- LoVo-OXP cells (derived from LoVo cells grown in the presence of increased concentrations of oxaliplatin) were 17-fold more resistant than parental cells (see Table 2).
- Table 2 The data reported in Table 2 clearly indicate that compound 1 is as good as oxaliplatin and better than cisplatin (particularly in the case of colon cancer cells) towards the sensitive lines.
- compound 1 does not show cross-resistance with cisplatin (RF 0.9), nor with oxaliplatin (RF 1.2).
- oxaliplatin is partially cross-resistant with cisplatin (RF 2.0) and cisplatin partially cross-resistant with oxaliplatin (RF 1.7).
- Compound 2 which has the same diamine as oxaliplatin but two leaving chlorides like cisplatin and compound 1, is, on the average, 5-10 times less effective than compound 1 and exhibits partial cross-resistance to both cisplatin (RF 2.0) and oxaliplatin (RF 2.6).
- Compound 5 was found to possess a cytotoxic activity better than cisplatin and similar to oxaliplatin against sensitive cells, showing no cross-resistance with both oxaliplatin (RF 1.4) and cislatin (RF 1.6).
- Compound 6 was less effective than oxaliplatin and cisplatin towards both ovarian and colon cancer cells. However, compounds 6 was only partially cross-resistant with oxaliplatin and cisplatin (RFs 1.9).
- Compound 7 was less effective than oxaliplatin and cisplatin towards both ovarian and colon cancer cells. However, it was able to overcome both cisplatin (RFs 1.3) and oxaliplatin resistances (RF 1.1).
- Compound 8 was found to possess a cytotoxic activity lower than cisplatin and oxaliplatin in ovarian sensitive cancer cells, similar than cisplatin against colon sensitive cells, and showing no cross-resistance with both oxaliplatin (RF 0.8) and cisplatin (RF 1.2).
- MDR multidrug resistant colon carcinoma subline
- LoVo MDR multidrug resistant
- doxorubicin a drug belonging to the MDR spectrum
- P-gp multi-specific drug transporters
- MRP1, MRP2, MRP4 multidrug resistance proteins
- LoVo and LoVo-OXP cells (2 ⁇ 10 6 ) were seeded in 75 cm 2 flasks in growth medium (20 ml). After 24 h, the medium was replaced and the cells incubated for different times (6, 24 or 48 h) in the presence of the tested complexes. Cell monolayers were washed twice with cold PBS and harvested. Samples were subjected to three freezing/thawing cycles at ⁇ 80° C., and then vigorously vortexed. Aliquots were removed for the determination of protein content by the BioRad protein assay (BioRad).
- cisplatin and oxaliplatin are distribution in the body, cellular accumulation, and recognition and processing of DNA adducts. These differences are ascribable, at least in part, to the presence of the organic diamine ligand in oxaliplatin, which confers lipophilicity and steric bulk.
- other groups have pursued the preparation of platinum derivatives having methyl-substituted 1R,2R-DACH ligand with the aim of improving the cytotoxic and anticancer properties of the drug by increasing its lipophilicity and steric bulk (Abramkin, S. A., et al., J. Med. Chem. 2010, 53, 7356-7364).
- Lipophilicity is usually expressed in terms of n-octanol/water partition coefficient, log P o/w , and correlates with cellular uptake by passive diffusion (Liu, X., et al., Pharm. Res. 2011, 28, 962-977).
- mice All studies involving animal testing were carried out in accordance with the ethical guidelines for animal research adopted by the University of Padua, acknowledging the Italian regulation and the European Directive 86/609/EEC as to animal welfare and protection and the related codes of practice.
- the mice were purchased from Charles River, Italy, and housed in steel cages under controlled environmental conditions (constant temperature, humidity, and 12 h dark/light cycle) andfrod with commercial standard feed and tap water ad libitum. Animals were observed daily, and body weight and food intake recorded.
- the Lewis lung carcinoma (LLC) cell line was purchased from ECACC, UK.
- the LLC cell line was maintained in D-MEM (Euroclone) supplemented with 10% heat-inactivated FBS (Euroclone), 10 mM L-glutamine, 100 U mL ⁇ 1 penicillin, and 100 ⁇ g mL ⁇ 1 streptomycin in a 5% CO 2 air incubator at 37° C.
- mice The Lewis lung carcinoma (LLC) was implanted i.m. as a 2 ⁇ 10 6 cell inoculum into the right hind leg of 8-week old male and female C57BL mice (24 ⁇ 3 g body weight). After 24 h from tumor implantation, mice were randomly divided into five groups (8 animals per group, 10 controls) and treated with a daily i.p. injection of compound 1 (1.5 and 3 mg kg ⁇ 1 in 0.9% NaCl solution), cisplatin (1.5 mg kg ⁇ 1 in 0.9% NaCl solution), or the vehicle solution (0.9% NaCl solution) from day 9 after tumor inoculation (palpable tumor).
- compound 1 1.5 and 3 mg kg ⁇ 1 in 0.9% NaCl solution
- cisplatin 1.5 mg kg ⁇ 1 in 0.9% NaCl solution
- vehicle solution 0.9% NaCl solution
- mice were sacrificed, the legs were amputated at the proximal end of the femur, and the inhibition of tumor growth was determined according to the difference in weight of the tumor-bearing leg and the healthy leg of the animals expressed as % referred to the control animals. Body weight was measured every two days and was taken as a parameter for systemic toxicity.
- the in vivo antitumor activity of compound 1 was evaluated in a model of solid tumor, the syngeneic murine Lewis lung carcinoma (LLC). Tumor growth inhibition induced by compound 1 was compared with that promoted by the reference metallodrug cisplatin. From day 9 after tumor inoculation, when tumors became palpable, tumor-bearing mice received daily doses of compound 1 (1.5 and 3 mg kg ⁇ 1 ) or cisplatin (1.5 mg kg ⁇ 1 ). Tumor growth was estimated at day 15, and the results are summarized in Table 3. For the assessment of the adverse side effects, changes in body weights of tumor-bearing mice were monitored daily ( FIG. 3 ).
- Compound 1 is better tolerated than cisplatin and could be administered also at a greater dose (3 mg kg ⁇ 1 ).
- the inhibition of tumor cell proliferation for the three compounds is shown in Table 3.
- LoVo and LoVo-OXP tumor xenografts were established in 6-week-old BALB/c nu/nu mice by injecting 1 ⁇ 10 7 tumor cells subcutaneously (100 ⁇ L in serum free medium) on the left dorsal flank. After 24 h from tumor implantation, mice were randomly divided into five groups (6 animals per group, 8 controls). Chemotherapy was delayed until the tumor became palpable (day 14). From day 14, 1 was dosed daily at 3 mg/kg ip whereas OXP was dosed daily at 2 mg/kg ip. Measurements of body weights and tumor volumes were recorded every 2 days until the experimental endpoint.
- animals were sacrificed, and the inhibition of tumor growth was determined by comparing the volume of the control group and the treatment group expressed as % referred to the control animals.
- Compound 1 exerts a significant antitumor activity ( FIG. 4 ) against both on LoVo and LoVo-OXP colorectal adenocarcinoma xenografts, with a tumor growth inhibition of 61% and 58% in LoVo and LoVo-OXP models, respectively.
- the antitumor activity of oxaliplatin is comparable to that exerted by 1 against LoVo xenografts (tumor growth inhibition of 54%) but 2.4 times lower against LoVo-OXP models (tumor growth inhibition of 24%).
- the body weight loss (depicted in FIG. 5 ) induced by 1 was roughly equivalent to that obtained by using the parent drug oxaliplatin.
- the in vitro and in vivo results for compounds of the present invention and particularly compound 1 show exceptional and unexpected activity against oxaliplatin refractory tumors.
- Compound 1 structurally differs from oxaliplatin only in the different bridging mode of the DACH carrier ligand, which creates a 7 membered ring in the case of 1,4-DACH and a 5 membered ring in the case of 1,2-DACH.
- the in vitro data demonstrated that this bite dissimilarity did not confer significant differences in terms of DNA binding mode between compound 1 and oxaliplatin.
- the main molecular mechanisms accounting for oxaliplatin resistance are related to DNA damage, the present results are even more surprising and unexpected.
- ESI-MS spectra were recorded on Agilent 1100 Series LC-MSD-Trap-System VL.
- IR spectra were obtained on a Perkin-Elmer IR Fourier transform spectrophotometer in KBr pellets. Elemental analyses were carried out with a Hewlett Packard 185 C, H, and N analyzer.
- K 2 [PtCl 4 ] (0.726 g, 1.75 mmol) was dissolved in a minimum amount of water (15 mL) and the resulting red solution was treated with KI (1.74 g, 10.5 mmol). After stirring for 5 min, the brown solution was treated with 1R,2R-diaminocyclohexane (200 mg, 1.75 mmol) which caused the immediate formation of a yellow precipitate. The suspension was stirred for 3 h. The yellow precipitate, [PtI 2 (1R,2R-DACH)], was then collected by filtration, washed with water, ethanol, and diethylether, dried under vacuum, and analyzed by elemental analysis. A yield of 1.36 g (91%) was obtained.
- Oxalic acid [OXA, (COOH) 2 , 0.041 g, 0.45 mmol] was dissolved in water (40 mL) and the resulting solution was treated in the dark with Ag 2 O (0.104 g, 0.45 mmol) for 15 min at 50° C.
- the resulting suspension was added to [PtCl 2 (cis-1,4-DACH)] (0.171 g, 0.45 mmol), stirred with a magnetic stirrer in the dark at 50° C. for 90 min and then at room temperature for 24 h.
- the white precipitate that formed (AgCl) was filtered thorough celite and the filtrate evaporated under vacuum at 40° C.
- the light yellow residue (0.134 g, 0.34 mmol; yield 75%) corresponds to [Pt(OXA)(cis-1,4-DACH)].
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the use of certain platinum compounds including [PtCb(cis-1,4-diaminocyclohexane)], or combinations of these compounds with a variety of other agents for treating and/or preventing the progression of colorectal cancer in mammals. In particular, the invention provides methods of treating and/or preventing oxaliplatin-refractory colorectal cancer in mammals.
Description
- This application is a divisional application of U.S. Ser. No. 14/199,858 filed Mar. 6, 2014, now pending which claims benefit of provisional application U.S. Ser. No. 61/774,073 filed Mar. 7, 2013, all of which are incorporated herein by reference in their entirety.
- The present invention relates to the use of certain platinum compounds or combinations of these compounds with a variety of other therapeutic agents for treating and/or preventing the progression of colorectal cancer in mammals. In particular, the invention provides methods of treating and/or preventing oxaliplatin-refractory colorectal cancer in mammals.
- Platinum drugs (cisplatin, cis-diamminedichloroplatinum(II), CDDP; carboplatin, diammine[1,1-cyclobutanedicarboxylato]platinum(II); and oxaliplatin, [(1R,2R)-cyclohexane-1,2 diamine](ethanedioato)platinum(II);
FIG. 1 ) are widely used in the clinic and the prototype cisplatin still represents an antineoplastic drug with highly curative effects in a solid malignancy such as testicular cancer (Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. (Lippert, B., Eds.). Verlag Helvetica Chimica Acta, Zurich, 2000, 563 pp.; Jakupec, M. A., et al., Dalton Trans. 2008, 183-194; Kelland, L., Nat. Rev. Cancer 2007, 7, 573-584; Reedijk, J., Eur. J. Inorg. Chem. 2009, 1303-1312; Wong, E., et al., Chem. Rev. 1999, 99, 2451-2466; Hall, M. D., et al., J. Med. Chem. 2007, 50, 3403-3411; and Wheate, N. J., et al., Dalton Trans. 2010, 39, 8113-8127). The complex [PtCl2(cis-1,4-DACH)] (DACH=diaminocyclohexane), [SP-4-2-(cis)]-dichloro(1,4-cyclohexanediamine-N,N′)platinum, compound 1 (FIG. 1 ), contains an isomeric form of the diaminocyclohexane ligand found in oxaliplatin and has been widely investigated as a potential new platinum anticancer drug.Compound 1 also called “Kiteplatin” based on its structural features (Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830) resembling a parachute (the cis-1,4-DACH ligand) on a skydiver (the metal). U.S. Pat. No. 4,999,444 discloses a series of novel neutral mixed ligand platinum (II) and platinum (IV) complexes including [SP-4-2-(cis)]-dichloro(1,4-cyclohexanediamine,N,N′)platinum. - The first paper reporting the in vitro and in vivo activities of
compound 1 was published by Hoeschele, J. D., et al, J. Med. Chem. 1994, 37, 2630-2636. The in vitro growth inhibition data indicated thatcompound 1 exhibited potent activity in sensitive L1210 and P388 cell lines and that the compound also appeared more potent than cisplatin (based on ID50 values) against all tested Pt-resistant cell lines with the only exception of the cisplatin-resistant cell lines L1210PtR4 and L1210DDP5 (partial cross-resistance) and the oxaliplatin-resistant cell line L1210DACH. In vivo,compound 1 proved to be more dose potent than cisplatin (based on % T/C values) against the parental L1210 and P388 murine leukemias.Compound 1 also retained a significant activity against sublines derived from L1210 and P388 and made resistant to cisplatin. Bothcompound 1 and cisplatin produced equivalent activity against B16 melanoma and M5076 sarcoma, while cisplatin was more active thancompound 1 againstcolon carcinoma 26 at equitoxic doses. These initial data suggested that the spectrum of activity ofcompound 1 could have been different from those of cisplatin and oxaliplatin. - Two years later, Shamsuddin, S., et al., J. Inorg. Biochem. 1996, 61, 291-301 reported the in vitro cytotoxicity of
compound 1 against murine leukemia L1210 and human ovarian cancer A2780 cells. The compound was found to be more active than cisplatin and tetraplatin (PtIVCl4(1R,2R-DACH)) in both cell lines (the human A2780 cell line being more sensitive). The high potency and the high solubility in water ofcompound 1 made this compound an ideal lead for further studies. Khokhar and collaborators also explored PtIV(cis-1,4-DACH) derivatives (Shamsuddin, S., et al., J. Inorg. Biochem. 1998, 71, 29-35) and found that, among a series of complexes having the general formula cis,cis,trans-[PtIVCl2(cis-1,4-DACH)L2] (L=CH3(CH2)nCOO—, n=0-8), cis,cis,trans-[PtIVCl2(cis-1,4-DACH)(CH3COO)2] was the most active in the murine L1210 leukemia model. Khokhar and colleagues also prepared and characterized monofunctional (Ali, M. S., et al., J. Inorg. Biochem. 2003, 96, 452-456) and bifunctional (Shamsuddin, S., et al., Polyhedron. 2007, 26, 637-644) adducts ofcompound 1 with nucleobases as models for DNA binding of these Pt antitumor drugs (Wang, D., et al., Nat. Rev. Drug Discovery 2005, 4, 307-320 and Fuertes, M. A., et al., Chem. Rev. 2003, 103, 645-662). - A peculiar feature of platinum-coordinated cis-1,4-DACH is the formation of a seven-membered chelate ring, which is larger than the usually encountered five- and six-membered rings (X-ray diffraction data) (Hoeschele, J. D., et al, J. Med. Chem. 1994, 37, 2630-2636 and Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830). This results in a very large bite angle (≧97°) that could affect mobility of cis ligands. Indeed researchers investigated the (cis-1,4-DACH)PtG2 system (G=two untethered guanine bases) (Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830) and by lowering the temperature, were able to observe the presence of different rotamers in solution (two HT, head-to-tail, and one HH, head-to-head, conformers are possible in aqueous solution) (Natile, G., et al., Coord. Chem. Rev. 2006, 250, 1315-1331 and references therein).
- The unique antitumor activity of
compound 1 was further investigated with reference to: cell entry, reaction with sulfur-containing compounds, binding to DNA, and processing of DNA adducts by proteins (including DNA repair enzymes) (Kasparkova, J., et al., Biochem. Pharmacol. 2010, 79, 552-564). In particular, compared to cisplatin,compound 1 revealed: i) improved cytotoxicity (3.4-5.4-fold greater) and enhanced cellular uptake (ca. 1.5-fold greater) in human ovarian A2780 cancer cell line; ii) enhanced rate but similar sequence preference for DNA binding in cell-free media; iii) identical DNA interstrand cross-linking efficiency (6%); iv) similar bending (32°) but enhanced local DNA unwinding (ca. 1.5-fold greater) for 1,2-GG-intrastrand cross-links; v) markedly enhanced inhibition of DNA polymerase accompanied by significantly lower efficiency of DNA repair. - Later, in order to determine how the Y-family translesion DNA polymerase η (Polη) processes lesions generated by
complex 1, model systems employing a DNA double-base lesion derived from 1,2-GG intrastrand crosslinks of this complex were investigated (V. Brabec, J. Malina, N. Margiotta, G. Natile, J. Kasparkova. Chem. Eur. J. 2012, 18, 15439-15448). The catalytic efficiency of Polη for the insertion of correct dCTP, with respect to the other incorrect nucleotides, opposite the 1,2-GG cross-link was markedly reduced by the cis-1,4-DACH carrier ligand. This reduced efficiency of Polη to incorporate the correct dCTP could be due to a more extensive DNA unstacking and deformation of the minor groove induced in the DNA by the cross-link ofbulky complex 1. The major products of the bypass of this doublebase lesion produced bycomplex 1 by Polη resulted from misincorporation of dATP opposite the platinated G residues. The results of the investigation supported the thesis that the misincorporation could be due to sterical effects of the bulkier cis-1,4-DACH ligand hindering the formation of the Polη-DNA-incoming nucleotide complex. Calorimetric analysis suggested also that thermodynamic factors may contribute to the forces that governed enhanced incorporation of the incorrect dATP by Polη as well. - Colorectal cancer is at the top of the list of the most common cancers worldwide, with around 1 million new cases diagnosed every year (Van Cutsem, E., et al., J. Clin. Oncol. 2007, 25, 1658-1664). Early stage colorectal cancer is frequently curable with surgery, but the appearance of metastases leads to unresectable tissues with fatal consequences for the patient (Saltz, L. B., et al., J. Clin. Oncol. 2004, 22, 1201-1208). The best outcome in the therapy of metastatic colorectal cancer is obtained by the use of 5-fluorouracil, oxaliplatin, and irinotecan. More recently, biologic therapies have also proved to be effective in prolonging the median survival time (Sobrero, A. F., et al., J. Clin. Oncol. 2008, 26, 2311-2319).
- Presently, apart from oxaliplatin, there are no other drugs in advanced clinical development which appear to be active against colorectal cancer and that could be used for the treatment of patients with oxaliplatin-refractory colorectal cancer.
- Thus, there is considerable interest and an urgent need to find therapies to treat and or prevent oxaliplatin-refractory colorectal cancer. The present invention answers the need by providing compounds of formula I and formula II and in
particular compound 1. Therefore,compound 1 was evaluated against human colorectal cancer cells and, in particular, colorectal cancer cells resistant to oxaliplatin (Margiotta, N., et al., J. Med. Chem. 2012, 55(16), pp 7182-7192). We surprisingly and unexpectedly found that compounds of formula I and formula II and inparticular compound 1 was effective in treating refractory colorectal cancer and especially in circumventing cisplatin and oxaliplatin resistance in colorectal cancer. - In one embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I
- wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato, - in which R4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms,
- in which o is an integer from one to three and
- In another embodiment of the present invention R is —(CH2)n—, in which n is an integer from two to three; R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms or an alkoxy group of from one to four carbon atoms; and R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro and bromo or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of
- In another embodiment of the present invention R1 is hydrogen, carboxyl, methyl, or methoxy.
- In another embodiment of the present invention a compound of formula I is selected from the group consisting of:
- [SP-4-2-(cis)]-dichloro(1,4-cyclohexanediamine-N,N′)platinum;
- [SP-4-2-(cis)]-dichloro(1,3-cyclopentanediamine-N,N′)platinum;
- [SP-4-2-(cis)]-dichloro(1,4-cycloheptanediamine-N,N′)platinum;
- [SP-4-2-(cis)]-[1,1-cyclobutanedicarboxylato-(2-)O,O1](1,4-cyclohexanediamine-N,N′)platinum;
- [SP-4-2-(cis)]-(1,4-cyclohexanediamine-N,N′) [2-hydroxy-5-sulfobenzoato (3)-O1,O2]platinate (1-), hydrogen; and
- [SP-4-2-(cis)]-(1,4,cyclohexanediamine-N,N′)[ethanedioato(2)-O,O1]platinum.
- In another embodiment of the present invention a compound of formula I is
- In another embodiment of the present invention a compound of formula I is
- In another embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of compound of formula I
- wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato, - in which R4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms,
- in which o is an integer from one to three and
- and at least one carrier, diluent or excipient.
- In another embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I
- wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato, - in which R4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms,
- in which o is an integer from one to three and
- and at least one second therapeutic agent useful in treating colorectal cancer selected from the group consisting of: capecitabine; cetuximab; bevacizumab; a MEK inhibitor; a FOLFOX4 dosing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin; and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin.
- In another embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I and a MEK inhibitor which is N—[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, or a pharmaceutically acceptable salt thereof.
- In another embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
- wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato, - in which R4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms,
- in which o is an integer from one to three and
- and at least one second therapeutic agent useful in treating colorectal cancer selected from the group consisting of: capecitabine, cetuximab, bevacizumab, a MEK inhibitor, a FOLFOX4 dosing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin and at least one carrier, diluent or excipient.
- In another embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula II
- wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloroacetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato, - in which R4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms,
- in which o is an integer from one to three and
- and
R5 and R6 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, benzoato, 3,4,5-trihydroxybenzoato, 3,4,5-trimethoxybenzoato, R7(CH2)p—CO2— wherein R7 is selected from the group consisting of methyl, trifluoromethyl, CH2Cl, CH2Br, CH2F, CHCl2, CHBr2 and CHF2 and p is zero or an integer of one to five and R7(CH2)q—O— wherein R7 is defined above and q is zero or an integer of one to five. - In another embodiment of the present invention in a compound of Formula II R is —(CH2)n—, in which n is an integer from two to three; R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms or an alkoxy group of from one to four carbon atoms; and R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro and bromo or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of
- In another embodiment of the present invention in a compound of Formula II R1 is hydrogen, carboxyl, methyl, or methoxy.
- In another embodiment of the present invention a compound of formula II is selected from the group consisting of:
- (OC-6-33)-dichloro(cis-1,4-cyclohexanediamine-N,N′)bisdichloroacetateplatinum;
- [OC-6-22-(cis)]-tetrachloro(1,4-cyclohexanediamine-N,N′)platinum;
- (OC-6-33)-dichloro(cis-1,4-cyclohexanediamine-N,N′)dihydroxyplatinum;
- (OC-6-33)-[ethanedioato(2)-O,O′](cis-1,4-cyclohexanediamine-N,N′)dihydroxyplatinum; and
- (OC-6-33)-[ethanedioato(2)-O,O′](cis-1,4-cyclohexanediamine-N,N′)bisdichloroacetateplatinum.
- In another embodiment of the present invention a compound of formula II is
- In another embodiment of the present invention a compound of formula II is
- In another embodiment of the present invention a compound of formula II is
- In another embodiment of the present invention a compound of formula II is
- In another embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula II
- wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, and acetato and dichloroacetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato, - in which R4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms,
- in which o is an integer from one to three and
- and
R5 and R6 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, benzoato, 3,4,5-trihydroxybenzoato, 3,4,5-trimethoxybenzoato, R7(CH2)p—CO2— wherein R7 is selected from the group consisting of methyl, trifluoromethyl, CH2Cl, CH2Br, CH2F, CHCl2, CHBr2 and CHF2 and p is zero or an integer of one to five and R7(CH2)q—O— wherein R7 is defined above and q is zero or an integer of one to five and at least one carrier, diluent or excipient. - In another embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula II
- wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, nitrato, nitrito, acetato and dichloroacetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato, - in which R4 is hydrogen, hydroxyl, or an alkyl group of from one to four carbon atoms,
- in which o is an integer from one to three and
- and
R5 and R6 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, benzoato, 3,4,5-trihydroxybenzoato, 3,4,5-trimethoxybenzoato, R7(CH2)p—CO2— wherein R7 is selected from the group consisting of methyl, trifluoromethyl, CH2Cl, CH2Br, CH2F, CHCl2, CHBr2 and CHF2 and p is zero or an integer of one to five and R7(CH2)q—O— wherein R7 is defined above and q is zero or an integer of one to five and at least one second therapeutic agent useful in treating colorectal cancer selected from the group consisting of: capecitabine; cetuximab; bevacizumab; a MEK inhibitor; a FOLFOX4 dosing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin; and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin. - In another embodiment, the refractory colorectal cancer is oxaliplatin-refractory colorectal cancer.
- In another embodiment, the present invention is directed to treating a human.
- Additionally, another embodiment of the present invention is a compound having the following structure
- Additionally, another embodiment of the present invention is a compound having the following structure
-
FIG. 1 : Structures of Cisplatin, Carboplatin, Oxaliplatin, [PtCl2(1R,2R-DACH)] (Compound 2), and [PtCl2(cis-1,4-DACH)] (Compound 1). -
FIG. 2 : Intracellular accumulation of platinum complexes detected by GF-AAS analysis. LoVo (panel A) and LoVo-OXP (panel B) cells were incubated with 5 μM ofcompound 1,compound 2, and oxaliplatin (OXP) for 6, 24, and 48 h. Error bars indicate standard deviation. *p<0.05 and **p<0.01 compared to control, °p<0.05 compared to oxaliplatin treated cells. -
FIG. 3 : The body weight changes of LLC-bearing C57BL mice treated with vehicle or tested compounds. Each drug was administered daily fromday 9 and the weights were detected atday 1 and daily fromday 9. The error bars indicate the S.D. -
FIG. 4 : In vivo anticancer activity against LoVo and LoVo-OXP xenograft models. BALB/C nude mice bearing established human LoVo and LoVo OXP colorectal adenocarcinoma xenografts were daily ip dosed with either vehicle (Ctr) 0.9% NaCl, 1 at 3 mg/kg or OXP at 2 mg/kg fromday 14 today 30. The error bars indicate the SD. -
FIG. 5 : Body weight changes. The body weight changes of LoVo (panel A) and LoVo-OXP (panel B) xenograft mice treated with vehicle (Ctr) or tested compounds. Body weight was daily measured, fromday 14 today 30, and was taken as a parameter of systemic toxicity. The error bars indicate the SD. - In the compounds of Formula I and II the term “alkyl” means a straight or branched chain hydrocarbon group having from one to ten carbon atoms and includes for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, nonyl, and the like.
- “Alkoxy” is O-alkyl in which alkyl is as defined above.
- “Cycloalkyl” means a saturated hydrocarbon ring having three to six carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- “Hydroxyalkyl” means a hydroxy group attached to an alkyl radical in which alkyl is as defined above.
- “Halogen” is iodine, bromine, fluorine and chlorine.
- The term “mammal” refers to mice, rats, rabbits, guinea pigs, sheep, goats, cats, dogs, monkeys etc. Preferably, the term “mammal” refers to humans.
- The term “treating” refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition such as colorectal cancer. Preferably, “treating” refers to having a therapeutic effect in refractory colorectal cancer and more preferably “treating” oxaliplatin-refractory colorectal cancer.
- The term “preventing” refers to decreasing the probability that a mammal including a human contracts or develops colorectal cancer. Preferably, “preventing” refers to decreasing the probability that a mammal including a human contracts or develops refractory colorectal cancer and more preferably “preventing” oxaliplatin-refractory colorectal cancer.
- The term “refractory colorectal cancer” refers to a mammal including a human who is either initially unresponsive to therapy or who becomes unresponsive to therapy over time.
- The term “oxaliplatin-refractory colorectal cancer” refers to a mammal including a human who failed to respond to oxaliplatin-based therapy or whose disease has progressed after such treatment.
- DACH=diaminocyclohexane; DMSO=Dimethyl sulfoxide; DMF=dimethylformamide; GF-AAS=Graphite Furnace Atomic Absorption Analysis; HH=Head-to-Head; HT=Head-to-Tail; IC50=half-maximum inhibitory concentration; MM/QM=Molecular Mechanics/Quantum Mechanics; MRD=Multi-Drug Resistant; MRP=Multi-drug Resistance Protein; NER=Nucleotide Excision Repair; PBS=Phosphate Buffered Saline; P-gp=P-glycoprotein; RF=Resistance Factor; RP-HPLC=Reverse Phase High-Pressure Liquid Chromatography; S.D.=Standard Deviation; THF=tetrahydofuran.
- The neutral mixed ligand platinum complexes/compounds of formula I and formula II are restricted to the cis-geometric isomers. Complexes of formula I and formula II may also possess asymmetric carbon atoms (chiral centers) and thus the racemates, individual enantiomer as well as mixtures of enantiomers are also included within the scope of the invention.
- The compounds of the invention may exist in both unsolvated and solvated forms. The term ‘solvate’ is used herein to describe a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term ‘hydrate’ is employed when the solvent is water. Pharmaceutically acceptable solvates in accordance with the invention include hydrates and solvates wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMSO.
- The invention also includes isotopically-labeled compounds, which are identical to a compound of formula I or formula II, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, chlorine and platinum such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 36Cl, 191Pt and 195mPT respectively. Compounds of the present invention, which contain the aforementioned isotopes and/or other isotopes of other atoms, are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. An isotopically labeled compound of formula I or II of the invention can generally be prepared by carrying out the procedures described for the non-labeled compounds, substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- Also included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see Haleblian, J. K., Journal of Pharmaceutical Sciences, 1975, 64 (8), 1269-1288), the disclosure of which is incorporated herein by reference in its entirety.
- Compounds of Formula I and Formula II may be prepared according to the procedures described in the literature. See for example U.S. Pat. No. 4,999,444; Hoeschele, J., et al., J. Med. Chem. 1994, 37, 2630-2636; Shamsuddin, S., Inorg. Biochem. 1996, 61, 291-301; Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830; Dhara, S. C., Indian J. Chem. 1970, 8, 193-194; and Shamsuddin, S., J. Inorg. Biochem. 1998, 71, 29-35.
- The present invention also provides combinations, methods of using combinations and kits for use in combination therapies, using a compound of formula I or formula II and a variety of other therapeutic agents.
- In one embodiment, the present invention provides a method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I or II and at least one second therapeutic agent useful in treating colorectal cancer. For example, the second therapeutic agent may be selected from the group consisting of: capecitabine; cetuximab; bevacizumab; a MEK inhibitor such as N—[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, or a pharmaceutically acceptable salt thereof; a FOLFOX4 doing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin; and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin and the like. Effective dosages of a second therapeutic agent(s) would be known to one skilled in the art (see for example Physicians' Desk Reference 67th ed. 2013) and if needed may be further varied at the discretion of the prescribing physician.
- The compounds of the present invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
- Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be used as fillers in soft or hard capsules and typically include a pharmaceutically acceptable carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang, A. C. and Chen, L. H., Expert Opinion on Therapeutic Patents, 2001, 11 (6), 981-986, the disclosure of which is incorporated herein by reference in its entirety.
- For tablet dosage forms, depending on dose, the drug may make up from 1 wt % to 80 wt % of the dosage form, more typically from 5 wt % to 60 wt % of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt % to 25 wt %, preferably from 5 wt % to 20 wt % of the dosage form.
- Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose.
- Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
- Tablets may also optionally include surface active agents, such as sodium lauryl sulfate and
polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents are typically in amounts of from 0.2 wt % to 5 wt % of the tablet, and glidants typically from 0.2 wt % to 1 wt % of the tablet. - Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally are present in amounts from 0.25 wt % to 10 wt %, preferably from 0.5 wt % to 3 wt % of the tablet.
- Other conventional ingredients include anti-oxidants, colorants, flavoring agents, preservatives and taste-masking agents.
- Exemplary tablets contain up to about 80 wt % drug, from about 10 wt % to about 90 wt % binder, from about 0 wt % to about 85 wt % diluent, from about 2 wt % to about 10 wt % disintegrant, and from about 0.25 wt % to about 10 wt % lubricant.
- Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tableting. The final formulation may include one or more layers and may be coated or uncoated; or encapsulated.
- The formulation of tablets is discussed in detail in “Pharmaceutical Dosage Forms: Tablets, Vol. 1”, by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980, the disclosure of which is incorporated herein by reference in its entirety.
- Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- Suitable modified release formulations are described for example in U.S. Pat. No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles can be found, for example in Verma, R. K. and Garg, S., Pharmaceutical Technology On-line, 2001, 25(2), 1-14. The use of chewing gum to achieve controlled release for example is described in WO 00/35298. The disclosures of these references are incorporated herein by reference in their entireties.
- Additionally, the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including micro needle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- The solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
- Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and poly lactic-co-glycolic acid (PLGA) microspheres.
- Also, the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated; see, for example, Finnin, B. C. and Morgan, T. M., Journal of Pharmaceutical Sciences, 1999, 88 (10), 955-958. Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and micro needle or needle-free (e.g. Powderject™, Bioject™, etc.) injection. The disclosures of these references are incorporated herein by reference in their entireties.
- Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- Compounds of the invention may also be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
- Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- Finally, compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
- Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubilizer. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in PCT Publication Nos. WO 91/11172, WO 94/02518 and WO 98/55148, the disclosures of which are incorporated herein by reference in their entireties.
- The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is typically in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 0.01 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.07 to about 7000 mg/day, preferably about 0.7 to about 2500 mg/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be used without causing any harmful side effect, with such larger doses typically divided into several smaller doses for administration throughout the day.
- Inasmuch as it may desirable to administer a combination of active compounds, for example, for the purpose of treating and/or preventing refractory colorectal cancer, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions. Thus the kit of the invention includes two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
- The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically includes directions for administration and may be provided with a memory aid.
- The compounds of formula I and II are valuable anticancer agents. Thus, the anticancer activity of representative compounds of formula I and II were compared to other known anticancer platinum compounds in various in vitro and in vivo assays.
- Human breast (MCF-7) and colon (HCT-15, DDL1, SW480 and CaCo-2) carcinoma cell lines along with melanoma (A375) were obtained from the American Type Culture Collection (ATCC, Rockville, Md.). A431 are human cervical carcinoma cells kindly provided by Prof F Zunino (Molecular Pharmacology Unit, Experimental Oncology and Molecular Medicine, Istituto Nazionale dei Tumori, Milan, Italy). 2008 and its cisplatin resistant variant, C13*, are human ovarian cancer cell lines kindly provided by Prof. G. Marverti (Dept. of Biomedical Science, University of Modena, Italy). LoVo human colon-carcinoma cell line and its multidrug-resistant sublime (LoVo MDR) were kindly provided by Prof. F. Maj one (Department of Biology of Padova University, Italy). The LoVo-OXP cells were derived using a standard protocol in which LoVo cells were grown in increasing concentrations of oxaliplatin and resistant clones were selected over a period of nine months (Gandin, V., et al., J. Cell. Mol. Med. 2012, 16, 142-151). Cell lines were maintained in the logarithmic phase at 37° C. in a 5% carbon dioxide atmosphere using the following culture media containing 10% fetal calf serum (Euroclone, Milan, Italy), antibiotics (50 units mL−1 penicillin and 50 μg mL−1 streptomycin), and 2 mM L-glutamine in: i) RPMI-1640 medium (Euroclone) for MCF-7, HCT-15, A431,
DLD 1, 2008, and C13* cells; ii) F-12 HAM'S (Sigma Chemical Co.) for LoVo, LoVo MDR, and LoVo-OXP cells; iii) DMEM for A375 and SW 480 cells; and iv) MEM for CaCo-2 cells. - The growth inhibitory effect towards tumor cell lines was evaluated by means of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Alley, M. C., et al., Cancer Res. 1988, 48, 589-601).
- Briefly, depending upon the growth characteristics of the cell line, 3-8×103 cells well−1, were seeded in 96-well microplates in growth medium (100 μL) and then incubated at 37° C. in a 5% carbon dioxide atmosphere. After 24 h, the medium was removed and replaced with a fresh one containing the compound to be studied, at the appropriate concentration, dissolved in 0.9% sodium chloride solution just before use. Triplicate cultures were established for each treatment. After 72 h, each well was treated with 10 mL of a 5 mg mL−1 MTT saline solution and, after 5 h of incubation, 100 μL of a sodium dodecylsulfate (SDS) solution in 0.01 M HCl were added. After an overnight incubation, the inhibition of cell growth induced by the tested complexes was determined by measuring the absorbance of each well at 570 nm using a Bio-Rad 680 microplate reader. Mean absorbance for each drug dose was expressed as percentage of the control and plotted vs. drug concentration. Dose-response curves were fitted and IC50 values were calculated with four parameter logistic model (4PL). IC50 values represent the drug concentrations that reduce the mean absorbance at 570 nm to 50% of those in the untreated control wells.
-
Compound 1 was prepared for the first time almost twenty years ago however, until now, it had been tested (both in vitro and in vivo) only in a limited number of tumor cell lines (Hoeschele, J. D., et al., J. Med. Chem. 1994, 37, 2630-2636 and Shamsuddin, S., et al., J. Inorg. Biochem. 1996, 61, 291-301). - The Pt(II) and Pt(IV) complexes containing isomeric forms of diaminocyclohexane, [PtCl2(cis-1,4-DACH)] (1), [PtCl2(1R,2R-DACH)] (2), [Pt(OXA)(cis-1,4-DACH)] (3), cis,trans,cis-[PtIVCl2(OH)2(cis-1,4-DACH)] (4), cis,trans,cis-[PtIVCl2(DCA)2(cis-1,4-DACH)] (5), [Pt(CBDCA)(cis-1,4-DACH)] (6), cis,trans,cis-[PtIV(OXA)(OH)2(cis-1,4-DACH)] (7), and cis,trans,cis-[PtIV(OXA)(DCA)2(cis-1,4-DACH)] (8) were evaluated for their cytotoxic activity towards a panel of human tumor cell lines including cervical (A431), breast (MCF-7), cancers along with a melanoma (A375) and 4 different colon cancer cell lines corresponding to different stages of the disease progression (HCT-15, SW480, CaCo-2, DLD-1). The cytotoxicity was evaluated by means of the MTT test for 72 h treatment with increasing concentrations of the tested compounds. For comparison purposes, the cytotoxicity of cisplatin, the most widely used anticancer metallodrug, and oxaliplatin, key drug in FOLFOX (Folinic acid, 5-Fluorouracil & Oxaliplatin) regimens for the treatment of colorectal cancers, were evaluated in the same experimental conditions. IC50 values, calculated from dose-survival curves, are shown in Table 1.
-
TABLE 1 In vitro antitumor activitya IC50 (μM) ± S.D. Cell Tissue Compoundb line type 1 2 3 4 5 HCT-15 colon 2.66 ± 0.95 8.02 ± 1.84 12.23 ± 1.76 10.32 ± 1.42 3.16 ± 1.06 SW480 colon 2.12 ± 0.87 11.12 ± 2.05 7.42 ± 1.75 6.32 ± 2.15 3.02 ± 1.05 CaCo-2 colon 1.27 ± 0.65 16.26 ± 2.97 6.65 ± 1.25 7.12 ± 3.13 2.02 ± 0.84 DLD-1 colon 4.97 ± 0.53 8.06 ± 2.11 8.86 ± 1.11 7.74 ± 2.16 5.12 ± 0.94 MCF-7 breast 3.09 ± 1.06 9.52 ± 2.36 10.32 ± 2.41 7.01 ± 2.05 4.74 ± 1.15 A375 skin 1.87 ± 1.25 6.14 ± 1.45 12.07 ± 1.64 6.23 ± 1.96 3.06 ± 1.31 A431 cervix 1.46 ± 0.91 6.69 ± 3.27 7.14 ± 3.18 6.33 ± 1.99 3.03 ± 1.02 IC50 (μM) ± S.D. Cell Compoundb line 6 7 8 CDDP OXP HCT-15 31.85 ± 3.48 72.12 ± 4.74 13.69 ± 3.81 15.53 ± 2.48 1.25 ± 1.05 SW480 26.83 ± 2.87 69.41 ± 11.51 10.58 ± 2.01 7.67 ± 1.34 4.20 ± 0.75 CaCo-2 39.44 ± 3.35 97.28 ± 4.82 18.77 ± 2.81 18.31 ± 2.21 1.02 ± 0.25 DLD-1 29.76 ± 2.75 82.24 ± 5.54 8.26 ± 3.24 8.01 ± 2.22 5.81 ± 1.93 MCF-7 20.87 ± 2.98 112.1 ± 9.52 12.56 ± 2.47 8.37 ± 2.96 3.36 ± 1.69 A375 13.12 ± 3.58 75.14 ± 6.54 4.99 ± 1.15 2.06 ± 1.01 2.37 ± 1.31 A431 15.56 ± 2.85 59.53 ± 3.64 7.41 ± 2.11 1.96 ± 0.84 3.69 ± 1.03 aCells (3-8 × 104 m−1) were treated for 72 h with increasing concentrations of the test compounds. Cytotoxicity was assessed by MTT test. IC50 values were calculated by four parameter logistic model (p < 0.05). S.D. = standard deviation. b1: [PtCl2(cis-1,4-DACH)] 2: [PtCl2(1R,2R-DACH)] 3: [Pt(OXA)(cis-1,4-DACH)] 4: cis,trans,cis-[PtIVCl2(OH)2(cis-1,4-DACH)] 5: cis,trans,cis-[PtIVCl2(DCA)2(cis-1,4-DACH)] 6: [Pt(CBDCA)(cis-1,4-DACH)] 7: cis,trans,cis-[PtIV(OXA)(OH)2(cis-1,4-DACH)] 8: cis,trans,cis-[PtIV(OXA)(DCA)2(cis-1,4-DACH)] CDDP: cisplatin OXP: oxaliplatin -
Compound 1 was found, on average, slightly more effective than oxaliplatin, much more effective than cisplatin (by a factor of 3-6) in two out of the seven cell lines particularly in HCT-15 and CaCo-2 cells characterized for their scarce sensitivity to cisplatin, and, on the average, 2-4 times more active thancompound 2, which has the same diamine of oxaliplatin but chloride leaving ligands likecompound 1. - Compound 3 elicited an average cytotoxic activity lower than that of oxaliplatin and comparable to that of
compound 2 and cisplatin, being, however, 3 times more effective than cisplatin against CaCo-2 colon cancer cells. - Compound 4 possessed an average cytotoxic potency lower than oxaliplatin but slightly higher than cisplatin, with IC50 values in five out of the seven cell lines up to 2-fold lower than that of cisplatin.
- Compound 5 was found to possess, on average, a cytotoxic activity rather similar to oxaliplatin and roughly 3 times better than cisplatin and
compound 2. -
Compounds 6 and 7 possessed a mean cytotoxic potency lower than oxaliplatin and cisplatin. - Compound 8 elicited an average cytotoxic activity lower than that of oxaliplatin and comparable to that of cisplatin.
- The eight compounds were additionally tested for their in vitro antitumor activity in two pairs of human cell lines which were selected for their resistance to cisplatin (ovarian cancer cells 2008/C13*), or oxaliplatin (colon cancer cells LoVo/LoVo-OXP). A LoVo cell line retaining a multidrug resistance phenotype was also considered (LoVo MDR). Cross-resistance profiles were evaluated by means of the resistance factor (RF), which is defined as the ratio between the IC50 value for the resistant cells and that arising from the sensitive cells (Table 2).
-
TABLE 2 Cross-resistance profilesa IC50 (μm) ± S.D. Compoundb 2008 C13* R.F. LoVo LoVo-OXP R.F. LoVo-MDR R.F. 1 1.89 ± 1.04 1.77 ± 0.92 0.9 1.11 ± 0.45 1.29 ± 0.82 1.2 1.09 ± 0.46 1.2 2 8.57 ± 2.03 17.06 ± 1.35 2 5.62 ± 0.94 14.64 ± 1.84 2.6 5.07 ± 0.82 2.6 3 11.13 ± 2.98 15.63 ± 3.06 1.4 7.02 ± 0.56 12.53 ± 1.92 1.8 10.33 ± 2.73 1.5 4 9.42 ± 1.16 13.85 ± 3.53 1.5 6.64 ± 2.70 9.46 ± 2.15 1.6 9.26 ± 2.11 1.5 5 2.15 ± 0.95 3.35 ± 0.85 1.6 2.27 ± 1.31 3.23 ± 1.08 1.4 3.26 ± 1.13 1.5 6 27.23 ± 2.09 52.25 ± 4.21 1.9 29.32 ± 3.52 56.20 ± 4.41 1.9 42.23 ± 3.31 1.4 7 59.53 ± 3.64 78.72 ± 4.60 1.3 61.25 ± 5.51 66.88 ± 5.12 1.1 69.42 ± 4.83 1.1 8 11.12 ± 3.28 9.12 ± 2.79 0.8 9.08 ± 2.16 11.14 ± 3.05 1.2 11.86 ± 3.33 1.3 OXP 1.65 ± 1.01 3.33 ± 1.84 2 1.02 ± 0.56 17.50 ± 1.79 17 1.36 ± 0.81 1.3 CDDP 2.26 ± 1.06 23.73 ± 2.42 10.5 7.63 ± 1.53 13.13 ± 2.47 1.7 7.53 ± 0.98 1.1 aCells (3-8 × 104 mL−1) were treated for 72 h with increasing concentrations of tested compounds. Cytotoxicity was assessed by MTT test. IC50 values were calculated by four parameter logistic model (p < 0.05). S.D. = standard deviation. Resistant Factor (RF) is defined as IC50 resistant/parent line. b1: [PtCl2(cis-1,4-DACH)] 2: [PtCl2(1R,2R-DACH)] 3: [Pt(OXA)(cis-1,4-DACH)] 4: cis,trans,cis-[PtIVCl2(OH)2(cis-1,4-DACH)] 5: cis,trans,cis-[PtIVCl2(DCA)2(cis-1,4-DACH)] 6: [Pt(CBDCA)(cis-1,4-DACH)] 7: cis,trans,cis-[PtIV(OXA)(OH)2(cis-1,4-DACH)] 8: cis,trans,cis-[PtIV(OXA)(DCA)2(cis-1,4-DACH)] CDDP: cisplatin OXP: oxaliplatin - Cisplatin resistance is multifactorial in nature, however the main molecular mechanisms involved in drug resistance of C13* cancer cells have been identified in high cellular glutathione and thioredoxin reductase levels, in reduced cellular drug uptake, and in enhanced repair of DNA damage. The molecular mechanisms involved in oxaliplatin resistance have not been so well characterized, however they appear to be: i) decreased cellular accumulation, which is thought to be related to a greater activity of the ATP7B exporter rather than to the activity of P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1), and ii) more efficient repair of oxaliplatin induced DNA damage by NER (Nucleotide Excision Repair) (Zhou, Y., et al., World J. Gastroenterol., 2010, 16, 2291-2297; Kamazawa, S., et al., Gynecol. Oncol., 2002, 86, 171-176; Zhang, Y. H., et al., Cancer Lett., 2010, 291, 76-82; and Noordhuis, P., et al., Biochem. Pharmacol. 2008, 76, 53-61).
- It is noteworthy that, although oxaliplatin induces the same type of DNA crosslinks as cisplatin, it is effective also in cell lines resistant to cisplatin, thus suggesting that the two complexes may have different mechanism of resistance (Gatti, L.; Perego, P. Cellular resistance to oxaliplatin and drug accumulation defects. In: Bonetti, A. et al., editors. Cancer drug discovery and development platinum and other heavy metal compounds in cancer chemotherapy. New York: Humana Press; 2009. p. 115-124).
- LoVo-OXP cells (derived from LoVo cells grown in the presence of increased concentrations of oxaliplatin) were 17-fold more resistant than parental cells (see Table 2). The data reported in Table 2 clearly indicate that
compound 1 is as good as oxaliplatin and better than cisplatin (particularly in the case of colon cancer cells) towards the sensitive lines. Moreover,compound 1 does not show cross-resistance with cisplatin (RF 0.9), nor with oxaliplatin (RF 1.2). On the other hand, oxaliplatin is partially cross-resistant with cisplatin (RF 2.0) and cisplatin partially cross-resistant with oxaliplatin (RF 1.7).Compound 2, which has the same diamine as oxaliplatin but two leaving chlorides like cisplatin andcompound 1, is, on the average, 5-10 times less effective thancompound 1 and exhibits partial cross-resistance to both cisplatin (RF 2.0) and oxaliplatin (RF 2.6). - Compounds 3 and 4 were less effective than oxaliplatin and cisplatin towards ovarian sensitive cell line and rather similar to cisplatin against LoVo colon cancer cells. However, compounds 3 and 4 did show cross-resistance with ciplatin (RF 1.4 and 1.5, respectively), but were only partially cross-resistant with oxaliplatin (RF 1.8 and 1.6, respectively).
- Compound 5 was found to possess a cytotoxic activity better than cisplatin and similar to oxaliplatin against sensitive cells, showing no cross-resistance with both oxaliplatin (RF 1.4) and cislatin (RF 1.6).
-
Compound 6 was less effective than oxaliplatin and cisplatin towards both ovarian and colon cancer cells. However, compounds 6 was only partially cross-resistant with oxaliplatin and cisplatin (RFs 1.9). - Compound 7 was less effective than oxaliplatin and cisplatin towards both ovarian and colon cancer cells. However, it was able to overcome both cisplatin (RFs 1.3) and oxaliplatin resistances (RF 1.1).
- Compound 8 was found to possess a cytotoxic activity lower than cisplatin and oxaliplatin in ovarian sensitive cancer cells, similar than cisplatin against colon sensitive cells, and showing no cross-resistance with both oxaliplatin (RF 0.8) and cisplatin (RF 1.2).
- These findings are in agreement with those previously reported for human ovarian 2780/2870R cancer cells, (Kasparkova, J., et al., Biochem. Pharmacol. 2010, 79, 552-564) and for murine leukemia [PtCl2(1,2-DACH)]-resistant cells (Hoeschele, J. D., et al., J. Med. Chem. 1994, 37, 2630-2636).
- Therefore, it is possible to conclude that in human colorectal cancer cells compounds 1, 3, 4 and 5 are not recognized as a Pt(DACH) complex confirming that differences in shape of the diamine ligand can play a key role in the antitumor effect of Pt(DACH) complexes.
- In Table 2 are also reported the results obtained in a multidrug resistant (MDR) colon carcinoma subline, LoVo MDR, in which the resistance to doxorubicin, a drug belonging to the MDR spectrum, is associated with an overexpression of multi-specific drug transporters, such as the 170 kDa P-glycoprotein (P-gp) (Wersinger, C., et al., Amino Acids 2000, 19, 667-685). It is well known that acquired MDR, whereby cells become refractory to multiple drugs, poses most important challenge to the success of anticancer chemotherapy. Although cisplatin is not a P-glycoprotein substrate, many multidrug resistance proteins (MRP1, MRP2, MRP4) have been claimed to be involved in platinum complex transport and be responsible for its afflux to/efflux from the cell (Zhou, Y., et al., World J. Gastroenterol., 2010, 16, 2291-2297; Kamazawa, S., et al., Gynecol. Oncol., 2002, 86, 171-176; and Zhang, Y. H., et al., Cancer Lett., 2010, 291, 76-82).
- All platinum derivatives tested against this cell line showed a similar response as for the parental subline, thus suggesting that platinum drugs are not P-gp substrates.
- LoVo and LoVo-OXP cells (2×106) were seeded in 75 cm2 flasks in growth medium (20 ml). After 24 h, the medium was replaced and the cells incubated for different times (6, 24 or 48 h) in the presence of the tested complexes. Cell monolayers were washed twice with cold PBS and harvested. Samples were subjected to three freezing/thawing cycles at −80° C., and then vigorously vortexed. Aliquots were removed for the determination of protein content by the BioRad protein assay (BioRad). The samples were treated with 1 mL of highly pure nitric acid (Pt: ≦0.01 μg×kg−1, TraceSELECT® Ultra, Sigma Chemical Co.) and transferred into a microwave teflon vessel. Subsequently, samples were submitted to a standard procedure using a speed wave MWS-3 Berghof instrument (Eningen, Germany). After cooling, each mineralized sample was analyzed for platinum by using a Varian AA Duo graphite furnace atomic absorption spectrometer (Varian, Palo Alto, Calif.; USA) at the wavelength of 324.7 nm. The calibration curve was obtained using known concentrations of standard solutions purchased from Sigma Chemical Co.
- It is well-known that cellular uptake is an important factor influencing drug efficacy. Moreover, since one of the main mechanisms controlling oxaliplatin resistance is cellular uptake, uptake experiments were performed in human colorectal cancer cells sensitive and resistant to oxaliplatin. Cancer cells were treated for 6, 24, and 48 h with 5 μM concentrations of
compounds FIG. 2 . - The platinum cellular uptake was time dependent for all platinum complexes and for sensitive as well as for resistant LoVo cells (
FIG. 2 ). There is, however, a marked difference between sensitive and resistant cells as far as the discrimination between different complexes is concerned. In LoVo sensitive cells (FIG. 2 , panel A) the amount of incorporated drug is practically the same for the three types of complexes, clearly indicating that the smaller activity ofcompound 2 in this colon tumor cell line is to be ascribed to factors other than cellular drug uptake. In resistant LoVo-OXP cells (FIG. 2 , panel B) the cellular uptake is remarkably decreased for oxaliplatin and compound 2 (both compounds having the 1,2-DACH ligand) but not forcompound 1 which is internalized with the same efficacy in LoVo as well as in LoVo-OXP cells. These data can well explain the lack of cross-resistance betweencompound 1 and oxaliplatin. It is also to be noted that while forcompound 2 the observed RF (2.6) can be accounted for by the reduced cellular uptake, in the case of oxaliplatin the observed RF (17.0) is far too great to be justified only on the basis of differential cellular uptake. - The main differences between cisplatin and oxaliplatin are distribution in the body, cellular accumulation, and recognition and processing of DNA adducts. These differences are ascribable, at least in part, to the presence of the organic diamine ligand in oxaliplatin, which confers lipophilicity and steric bulk. On this basis, other groups have pursued the preparation of platinum derivatives having methyl-substituted 1R,2R-DACH ligand with the aim of improving the cytotoxic and anticancer properties of the drug by increasing its lipophilicity and steric bulk (Abramkin, S. A., et al., J. Med. Chem. 2010, 53, 7356-7364).
- It is generally found that the cellular uptake of platinum complexes correlates with their lipophilicities (Platts, J. A., et al, J. Med. Chem. 2001, 44, 472-474 and Ghezzi, A. R., et al., J. Inorg. Biochem. 2004, 98, 73-78).
- Lipophilicity is usually expressed in terms of n-octanol/water partition coefficient, log Po/w, and correlates with cellular uptake by passive diffusion (Liu, X., et al., Pharm. Res. 2011, 28, 962-977).
- Since RP-HPLC retention is due to partitioning between mobile (polar) and stationary (apolar) phases, there is a good correlation between capacity factor k′ (k′=(tR−t0)/t0, where t0 is the retention time for an unretained compound and tR is the retention time of the analyte) and partition coefficient (log Po/w=a+b log k′). Thus the HPLC procedure represents a good alternative to the time- and material-consuming shake-flask method. By using the HPLC procedure, log Po/w of
compound 1 was found to be −1.57±0.10 (Margiotta, N., et al., J. Med. Chem. 2012, 55(16), pp 7182-7192), in good agreement with that of compound 2 (log Po/w=−1.40) or oxaliplatin (log Po/w=−1.39) (Platts, J. A., et al., J. Inorg. Biochem. 2006, 100, 1199-1207) but significantly greater than that of cisplatin (log Po/w=−2.27) or [PtCl2(en)] (log Po/w=−2.16; en=ethylenediamine). Thus, the intracellular platinum accumulation exhibited bycompounds FIG. 2 panel A) appears to be strictly related to their very similar log Po/w, which could imply that the three complexes enter the cells by a similar route and this could be (but not exclusively be) passive diffusion. On the contrary, in the case of oxaliplatin-resistant LoVo-OXP cells, the cellular accumulation decreases remarkably forcompound 2 and oxaliplatin (containing 1,2-DACH ligand) but not for compound 1 (containing cis-1,4-DACH). This implies that there are specific import (CTR1, OCT, etc.) or export (ATP7B) mechanisms which operate selectively on the different types of complexes. - All studies involving animal testing were carried out in accordance with the ethical guidelines for animal research adopted by the University of Padua, acknowledging the Italian regulation and the European Directive 86/609/EEC as to animal welfare and protection and the related codes of practice. The mice were purchased from Charles River, Italy, and housed in steel cages under controlled environmental conditions (constant temperature, humidity, and 12 h dark/light cycle) and alimented with commercial standard feed and tap water ad libitum. Animals were observed daily, and body weight and food intake recorded. The Lewis lung carcinoma (LLC) cell line was purchased from ECACC, UK. The LLC cell line was maintained in D-MEM (Euroclone) supplemented with 10% heat-inactivated FBS (Euroclone), 10 mM L-glutamine, 100 U mL−1 penicillin, and 100 μg mL−1 streptomycin in a 5% CO2 air incubator at 37° C.
- The Lewis lung carcinoma (LLC) was implanted i.m. as a 2×106 cell inoculum into the right hind leg of 8-week old male and female C57BL mice (24±3 g body weight). After 24 h from tumor implantation, mice were randomly divided into five groups (8 animals per group, 10 controls) and treated with a daily i.p. injection of compound 1 (1.5 and 3 mg kg−1 in 0.9% NaCl solution), cisplatin (1.5 mg kg−1 in 0.9% NaCl solution), or the vehicle solution (0.9% NaCl solution) from
day 9 after tumor inoculation (palpable tumor). Atday 15, animals were sacrificed, the legs were amputated at the proximal end of the femur, and the inhibition of tumor growth was determined according to the difference in weight of the tumor-bearing leg and the healthy leg of the animals expressed as % referred to the control animals. Body weight was measured every two days and was taken as a parameter for systemic toxicity. - All the values are the means±S.D. of not less than three measurements. Multiple comparisons were made by Tukey-Kramer test (**p<0.01; *p or °p<0.05).
- The in vivo antitumor activity of
compound 1 was evaluated in a model of solid tumor, the syngeneic murine Lewis lung carcinoma (LLC). Tumor growth inhibition induced bycompound 1 was compared with that promoted by the reference metallodrug cisplatin. Fromday 9 after tumor inoculation, when tumors became palpable, tumor-bearing mice received daily doses of compound 1 (1.5 and 3 mg kg−1) or cisplatin (1.5 mg kg−1). Tumor growth was estimated atday 15, and the results are summarized in Table 3. For the assessment of the adverse side effects, changes in body weights of tumor-bearing mice were monitored daily (FIG. 3 ). -
Compound 1 is better tolerated than cisplatin and could be administered also at a greater dose (3 mg kg−1). The inhibition of tumor cell proliferation for the three compounds is shown in Table 3. -
TABLE 3 In vivo anticancer activity toward murine Lewis lung carcinoma (LLC). Starting from day 9 after tumor implantation, tested compounds weredaily administered i.p. At day 15, mice were sacrificed and tumor growthwas detected as described above. Tukey-Kramer test **p < 0.01. Daily dose i.p. Average tumor weight Inhibition of tumor (mg kg−1) (mean ± SD, g) growth (%) Controla — 0.778 ± 0.05 — 1 1.5 0.253 ± 0.09** 67.48 1 3 0.158 ± 0.06** 79.69 cisplatin 1.5 0.199 ± 0.10** 74.66 aVehicle (0.9% NaCl). - Even at the lower daily dose of 1.5 mg kg−1,
compound 1 exerts a statistically significant (p<0.01) antitumor activity, with a tumor growth inhibition of 67%. A reduction (about 80%) of the tumor volume was achieved using a daily dose of 3.0 mg kg−1. The antitumor activity of cisplatin (75%) is in between those obtained withcompound 1 at the two different doses. It is however remarkable that the body weight loss (depicted inFIG. 3 ) indicates that, even at the higher dose (3 mg kg−1),compound 1 had smaller adverse side effects than cisplatin and that, at equimolar dose (1.5 mg kg−1), the weight loss caused bycompound 1 is about half that caused by cisplatin. - LoVo and LoVo-OXP tumor xenografts were established in 6-week-old BALB/c nu/nu mice by injecting 1×107 tumor cells subcutaneously (100 μL in serum free medium) on the left dorsal flank. After 24 h from tumor implantation, mice were randomly divided into five groups (6 animals per group, 8 controls). Chemotherapy was delayed until the tumor became palpable (day 14). From
day day 30, animals were sacrificed, and the inhibition of tumor growth was determined by comparing the volume of the control group and the treatment group expressed as % referred to the control animals. - All the values are the means±S.D. of not less than three measurements. Multiple comparisons were made by Tukey-Kramer test (**p<0.01; *p<0.05).
-
Compound 1 exerts a significant antitumor activity (FIG. 4 ) against both on LoVo and LoVo-OXP colorectal adenocarcinoma xenografts, with a tumor growth inhibition of 61% and 58% in LoVo and LoVo-OXP models, respectively. Conversely, the antitumor activity of oxaliplatin is comparable to that exerted by 1 against LoVo xenografts (tumor growth inhibition of 54%) but 2.4 times lower against LoVo-OXP models (tumor growth inhibition of 24%). Notably, the body weight loss (depicted inFIG. 5 ) induced by 1 was roughly equivalent to that obtained by using the parent drug oxaliplatin. - These in vivo data confirm the effectiveness of 1 in circumventing oxaliplatin resistance in LoVo-OXP colorectal adenocarcinoma models.
- The unique antitumor effects of
compound 1, coupled with its enhanced aqueous solubility compared tocompound 2, make this compound a valuable agent against oxaliplatin-resistant colorectal cancer cells. - In summary, the in vitro and in vivo results for compounds of the present invention and particularly
compound 1 show exceptional and unexpected activity against oxaliplatin refractory tumors.Compound 1 structurally differs from oxaliplatin only in the different bridging mode of the DACH carrier ligand, which creates a 7 membered ring in the case of 1,4-DACH and a 5 membered ring in the case of 1,2-DACH. The in vitro data demonstrated that this bite dissimilarity did not confer significant differences in terms of DNA binding mode betweencompound 1 and oxaliplatin. As it is well recognized that in cancer cells the main molecular mechanisms accounting for oxaliplatin resistance are related to DNA damage, the present results are even more surprising and unexpected. In spite of the fact thatcompound 1 interacts with DNA in a similar manner to oxaliplatin, it retains an unexpected ability in overcoming oxaliplatin resistance in colon cancer cells. At the present time, oxaliplatin resistance remains a major clinical challenge in combination chemotherapy treatment based on platinum drugs. Presently, apart from oxaliplatin, there are no other drugs in advanced clinical development which appear to be active against colorectal cancer and that may be used for the treatment of patients with oxaliplatin-refractory colorectal cancer. Based on the in vitro and in vivo data the compounds of the present invention and in particular the data forcompound 1 fulfill a current pressing need for new antitumor agents for the treatment of oxaliplatin resistant colon cancer. - The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention.
- 1H 1D and 2D NMR spectra were recorded on Bruker Avance DPX 300, Bruker Avance II 600 MHz, and Bruker Avance III 700 MHz instruments. 195Pt NMR spectra were recorded on a Bruker Avance DPX 300 MHz instrument. 1H chemical shifts were referenced using the internal residual protic peak of the solvent (2.50 ppm for DMSO-d6, 8.03 ppm for DMF-d7, 4.8 ppm for D2O). 195Pt NMR spectra were referenced relative to K2PtCl4 (external standard placed at −1620 ppm with respect to Na2[PtCl6]). ESI-MS spectra were recorded on Agilent 1100 Series LC-MSD-Trap-System VL. IR spectra were obtained on a Perkin-Elmer IR Fourier transform spectrophotometer in KBr pellets. Elemental analyses were carried out with a Hewlett Packard 185 C, H, and N analyzer.
-
- [PtCl2(cis-1,4-DACH)],
compound 1, was prepared according to the procedure described by Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830. -
- [PtCl2(1R,2R-DACH)],
compound 2, was prepared using the methodology described in Dhara, S. C., Indian J. Chem. 1970, 8, 193-194. - Briefly, K2[PtCl4] (0.726 g, 1.75 mmol) was dissolved in a minimum amount of water (15 mL) and the resulting red solution was treated with KI (1.74 g, 10.5 mmol). After stirring for 5 min, the brown solution was treated with 1R,2R-diaminocyclohexane (200 mg, 1.75 mmol) which caused the immediate formation of a yellow precipitate. The suspension was stirred for 3 h. The yellow precipitate, [PtI2(1R,2R-DACH)], was then collected by filtration, washed with water, ethanol, and diethylether, dried under vacuum, and analyzed by elemental analysis. A yield of 1.36 g (91%) was obtained. [PtI2(1R,2R-DACH)] (182 mg, 0.32 mmol) was then suspended in 20 mL of water and treated with AgNO3 (109 mg, 0.64 mmol) which caused the immediate formation of a yellow precipitate (AgI). The suspension was kept at 55° C. in the dark for 30 min, AgI was separated by filtration of the mother liquor through celite, and the filtrate was treated with KCl (1.43 g, 1.92 mmol). The resulting solution was stirred at 55° C. for 30 min, resulting in the formation of a yellow precipitate. The yellow precipitate, corresponding to compound 2, was isolated by filtration, washed with ice-cold water, ethanol, and ether and then dried under vacuum. A yield of 0.30 g (94%) was obtained.
- The elemental analyses and the spectroscopic and spectrometric properties of the synthesized Pt-complexes were consistent with the data reported in the literature (Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830 and Kidani, Y, et al., J. Med. Chem. 1978, 21, 1315-1318). The purity of synthesized compounds was higher than 95% as established by combustion analysis.
-
- Oxalic acid [OXA, (COOH)2, 0.041 g, 0.45 mmol] was dissolved in water (40 mL) and the resulting solution was treated in the dark with Ag2O (0.104 g, 0.45 mmol) for 15 min at 50° C. The resulting suspension was added to [PtCl2(cis-1,4-DACH)] (0.171 g, 0.45 mmol), stirred with a magnetic stirrer in the dark at 50° C. for 90 min and then at room temperature for 24 h. The white precipitate that formed (AgCl) was filtered thorough celite and the filtrate evaporated under vacuum at 40° C. The light yellow residue (0.134 g, 0.34 mmol; yield 75%) corresponds to [Pt(OXA)(cis-1,4-DACH)].
- 1H NMR: (D2O) 5.29 (4H, NH2), 2.89 (2H, CHa, see Figure above for the numbering of protons), 3.21 (4H, CHa), 1.76 (8H, CHb) ppm. 195Pt NMR: (D2O) −1865 ppm. ESI-MS: calculated for [C8H14N2O4PtNa]+ [3+Na]+: 420.0. Found: m/z 420.0. Anal.: calculated for C8H16N2O5Pt (3.H2O): C, 23.14; H, 3.88; N, 6.74%. Found: C, 23.44; H, 3.61; N, 6.73%.
-
- cis,trans,cis-[PtCl2(OH)2(cis-1,4-DACH)], compound 4, was prepared using a modified method according to Shamsuddin, S., et al., J. Inorg. Biochem., 1998, 71, 29-35.
- Briefly, a suspension of [PtCl2(cis-1,4-DACH)] (compound 1) (208.6 mg, 0.55 mmol) in 28 mL of H2O was treated with a solution of H2O2 in H2O (30% w/w, 2.0 mL). The mixture was stirred in the dark at 70° C. for 2 h. The resulting yellow solution was filtered and then concentrated under reduced pressure to a minimum volume. Addition of acetone induced the formation of a pale yellow precipitate that was isolated by filtration of the mother liquor, washed with ice cold water, and dried under vacuum to afford 183 mg (0.44 mmol; 80% yield) of cis,trans,cis-[PtCl2(OH)2(cis-1,4-DACH)].
- 1H NMR: (DMSO-d6) 6.33 (4H, NH2), 2.89 (2H, CHa, see Figure above for the numbering of protons), 2.07 (4H, CHbHc), 1.45 (4H, CHbHc) ppm; (DMF-d7) 6.70 (4H, NH2), 3.25 (2H, CHa), 2.26 (4H, CHbHc), 1.67 (4H, CHbHc) ppm. 195Pt NMR: (DMSO-d6) 964.6 ppm; (DMF-d7) 871.7 ppm. IR: (KBr pellet) 3421, 3210, 1629, 1574, 547, 396, 322, 215 cm−1. ESI-MS: calculated for C6H16N2Cl2O2PtNa [4+Na]+: 437.01. Found: m/z 436.9. Anal.: calculated for C6H18N2Cl2O3Pt (4.H2O): C, 16.67; H, 4.20; N, 6.48%. Found: C, 16.42; H, 4.15; N, 6.29%.
-
- A suspension of cis,trans,cis-[PtIVCl2(OH)2(cis-1,4-DACH)], compound 4, (example 4, 43 mg, 0,104 mmol) in THF (2 mL) was treated with dichloroacetic anhydride 125 mL. The mixture was stirred using a magnetic stirrer in the dark at room temperature for 17 h. The resulting yellow solution was treated with n-pentane until precipitation of a light yellow solid, which was isolated by filtration, washed with n-pentane and then with ice-cold water and finally dried under vacuum to afford 441 mg (62% yield) of cis,trans,cis-[PtIVCl2(DCA)2(cis-1,4-DACH)].
- 1H-NMR (DMSO-d6): 7.92 (4H, NH2), 6.58 (2H, CHc), 3.03 (2H, CHa), 1.63 (8H, CHb) ppm. 195Pt NMR (DMSO-d6): 1195 ppm. ESI-MS: calculated for [C10H16N2Cl6O4PtNa]+ [5+Na]+: 659.0. Found: m/z 658.7. Anal.: calculated for C10H16N2Cl6O4Pt (5): C, 18.88; H, 2.54; N, 4.40%. Found: C, 18.76; H, 2.58; N, 4.35%.
-
- [Pt(CBDCA)(cis-1,4-DACH)],
compound 6, was prepared according to the procedure described by Ranaldo, R., et al., Inorg. Chem. 2008, 47, 2820-2830. -
- A solution of [Pt(OXA)(cis-1,4-DACH)] (170 mg, 0.428 mmol; this compound was prepared using the methodology described in S. Shamsuddin, I. Takahashi, Z. H. Siddik, A. R. Khokhar. J. Inorg. Biochem. 1996, 61, 291-301) in 17 mL of H2O was treated with a 855 μL of a solution of H2O2 in H2O (30% w/w). The mixture was stirred at room temperature for 24 h in the dark. The resulting suspension was concentrated under reduced pressure to a minimum volume. Addition of acetone induced the formation of a white precipitate that was isolated by filtration of the mother liquor, washed with acetone, and dried under vacuum. Yield 83% (151 mg, 0.35 mmol).
- Anal.: calculated for C8H16N2O6Pt.0.5H2O (cis,trans,cis-[Pt(OXA)(OH)2(cis-1,4-DACH)].0.5H2O) C, 21.82; H, 3.89; N, 6.36%. Found: C, 21.83; H, 3.94; N, 6.13%.
- ESI-MS: calculated for C8H16N2O6PtK [7+K]+ 470.39. Found: m/z 470.03
- 1H-NMR (DMSO-d6): 6.71 (4H, NH2), 2.91 (2H, CHa), 1.97 (2H, CHb), 1.50 (8H, CHc), 0.77 (2H, OH) ppm.
-
- Dichloroacetic anhydride (282.5 μL, 1.85 mmol) was added to a suspension of cis,trans,cis-[Pt(OXA)(OH)2(cis-1,4-DACH)] (compound 7) (100 mg, 0.232 mmol) in 7 mL of THF. The reaction mixture was stirred in the dark at room temperature for 17 h. The resulting white precipitate was isolated by filtration, washed with n-pentane and dried under vacuum. Yield 75.6% (117.3 mg, 0.18 mmol). Anal.: calculated for C12H16Cl4N2O8Pt (cis,trans,cis-[Pt(OXA)(DCA)2(cis-1,4-DACH)]) C, 22.07; H, 2.47; N, 4.29%. Found: C, 22.46; H, 2.73; N, 4.44%.
- ESI-MS: calculated for C12H15Cl4N2O8Pt [8-H]− 650.92 Found: m/z 650.93.
- 1H-NMR (DMSO-d6): 7.69 (4H, NH2), 6.53 (2H, CHd), 0.2.98 (2H, CHa), 1.72 (8H, CHb/c) ppm.
- All publications including but not limited to journal articles, books, patents, patent applications, etc. described in this application are each herein incorporated by reference in their entirety.
- Although the invention has been described herein with reference to the disclosed embodiments, persons skilled in the art will appreciate that the specific procedures, experiments, etc. detailed are illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Therefore, the invention is limited only by the following claims.
Claims (19)
1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. A method of treating refractory colorectal cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula II
wherein R is —(CH2)n— in which n is an integer from one to three;
R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms, an alkyl group of from one to four carbon atoms substituted with an alkoxy group of from one to four carbon atoms, a cycloalkyl group of from three to six carbon atoms, a hydroxyalkyl group of from one to four carbon atoms, an alkoxy group of from one to four carbon atoms or benzyl; and
R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, acetato and dichloracetato or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of sulfato, oxalato,
and
R5 and R6 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro, bromo, iodo, hydroxo, nitrato, nitrito, benzoato, 3,4,5-trihydroxybenzoato, 3,4,5-trimethoxtbenzoato, R7(CH2)p—CO2— wherein R, is selected from the group consisting of methyl, trifluoromethyl, CH2Cl, CH2Br, CH2F, CHCl2, CHBr2 and CHF2 and p is zero or an integer of one to five and R7(CH2)q—O— wherein R7 is defined above and q is zero or an integer of one to five.
12. The method of claim 11 wherein R is —(CH2)n—, in which n is an integer from two to three; R1 is hydrogen, carboxyl, an alkyl group of from one to four carbon atoms or an alkoxy group of from one to four carbon atoms; and R2 and R3 are negatively charged monodentate ligands which may be the same or different and are selected from the group consisting of chloro and bromo or R2 and R3 taken together form a dinegatively charged bidentate ligand selected from the group consisting of
13. The method of claim 12 wherein R1 is hydrogen, carboxyl, methyl, or methoxy.
14. The method of claim 11 wherein a compound of formula II is selected from the group consisting of:
(OC-6-33)-dichloro(cis-1,4-cyclohexanediamine-N,N′)bisdichloroacetateplatinum;
[OC-6-22-(cis)]tetrachloro(1,4-cyclohexanediamine-N,N′)platinum;
(OC-6-33)-dichloro(cis-1,4-cyclohexanediamine-N,N′)dihydroxyplatinum;
(OC-6-33)-[ethanedioato(2)-O,O′](cis-1,4-cyclohexanediamine-N,N′)dihydroxyplatinum; and
(OC-6-33)-[ethanedioato(2)-O,O′](cis-1,4-cyclohexanediamine-N,N′)bisdichloroacetateplatinum.
16. The method of claim 11 wherein the refractory colorectal cancer is oxaliplatin-refractory cancer.
17. The method of claim 16 wherein the mammal is a human.
19. (canceled)
20. The method of claim 11 further comprising at least one second therapeutic agent useful in treating colorectal cancer selected from the group consisting of: capecitabine; cetuximab; bevacizumab; a MEK inhibitor; a FOLFOX4 dosing schedule consisting of oxaliplatin, 5-fluorouracil and leucovorin; and a FOLFIRI dosing schedule consisting of irinotecan, 5-fluorouracil and leucovorin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/943,859 US20160096855A1 (en) | 2013-03-07 | 2015-11-17 | Method of Treating Colorectal Cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361774073P | 2013-03-07 | 2013-03-07 | |
US14/199,858 US9220705B2 (en) | 2013-03-07 | 2014-03-06 | Method of treating colorectal cancer |
US14/943,859 US20160096855A1 (en) | 2013-03-07 | 2015-11-17 | Method of Treating Colorectal Cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/199,858 Division US9220705B2 (en) | 2013-03-07 | 2014-03-06 | Method of treating colorectal cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160096855A1 true US20160096855A1 (en) | 2016-04-07 |
Family
ID=51488091
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/199,858 Expired - Fee Related US9220705B2 (en) | 2013-03-07 | 2014-03-06 | Method of treating colorectal cancer |
US14/943,859 Abandoned US20160096855A1 (en) | 2013-03-07 | 2015-11-17 | Method of Treating Colorectal Cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/199,858 Expired - Fee Related US9220705B2 (en) | 2013-03-07 | 2014-03-06 | Method of treating colorectal cancer |
Country Status (1)
Country | Link |
---|---|
US (2) | US9220705B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3297636B1 (en) * | 2015-06-19 | 2021-02-17 | Syn-Nat Products Enterprise LLC | Pharmaceutical composition of carboplatin based co-crystals and use thereof |
CN116854745A (en) | 2015-06-25 | 2023-10-10 | 新纳特产品公司 | Pharmaceutical co-crystal composition and use thereof |
WO2024030189A1 (en) * | 2022-08-05 | 2024-02-08 | The Trustees Of Princeton University | Anticancer agent |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5393909A (en) * | 1988-11-22 | 1995-02-28 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
US5434256A (en) * | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6317894A (en) | 1986-07-09 | 1988-01-25 | Ajinomoto Co Inc | Novel platinum complex and use thereof |
US4999444A (en) * | 1989-03-10 | 1991-03-12 | Warner-Lambert Co. | Novel neutral mixed ligand platinum(II) and platinum(IV) complexes |
KR100484504B1 (en) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | Inclusion compound comprising curcurbituril derivatives as host molecule and pharmaceutical composition comprising the same |
-
2014
- 2014-03-06 US US14/199,858 patent/US9220705B2/en not_active Expired - Fee Related
-
2015
- 2015-11-17 US US14/943,859 patent/US20160096855A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5393909A (en) * | 1988-11-22 | 1995-02-28 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
US5434256A (en) * | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
Non-Patent Citations (3)
Title |
---|
Khokhar et al. CAS: 123:245295, 1995. * |
Shamsuddin et al. CAS: 124:343591,1996. * |
Shamsuddin et al., Journal of Inorganic Biochemistry, 1996, 61: 291-301. * |
Also Published As
Publication number | Publication date |
---|---|
US20140255394A1 (en) | 2014-09-11 |
US9220705B2 (en) | 2015-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3009850C (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
US20160096855A1 (en) | Method of Treating Colorectal Cancer | |
KR20090025247A (en) | Potentiator of radiation therapy | |
US11104692B1 (en) | Heterocyclic diazenyl pyridinone copper(II) complexes as pharmacological antitumor agents | |
EP2924044A1 (en) | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino | |
US20090137620A1 (en) | Use of gallium(iii) complexes for the treatment of melanomas | |
WO2006106984A1 (en) | Potentiator for radiation therapy comprising pyridine derivative as active ingredient | |
EP1377552A1 (en) | Metal complexes and therapeutic uses thereof | |
AU2002231463A1 (en) | Metal complexes and therapeutic uses thereof | |
EP2810649B1 (en) | Amino sugar-bound anti-cancerous noble metal complex | |
KR101360478B1 (en) | Novel Tetranuclear Arene-Ruthenium Compound and Parmaceutical Composition for Preventing or Treating Cancer Containing Thereof | |
US6921824B1 (en) | Ruthenium dimeric complexes suitable as antimetastatic and antineoplastic agents | |
US11571430B2 (en) | Platinum(II) ammine selenourea complexes and methods of treating cancer | |
EP2924045A1 (en) | New agents for the treatment of cancer | |
KR101394878B1 (en) | Novel hexanuclear Arene-Ruthenium nano prismatic cage compound, preparation method thereof and pharmaceutical composition for preventing and treating cancer as active ingredient | |
US20100152154A1 (en) | Novel platinum compounds for treating cancer | |
US9839643B2 (en) | Palladium complex with high anticancer activity | |
WO2021258173A1 (en) | Phenolic binucleating ligands, binuclear metal compounds, medical-veterinary composition, processes for synthesizing binucleating ligands, process for synthesizing binuclear compounds, method of treatment of neoplasms and fungal diseases and use | |
EP4355753A1 (en) | Complexes of cu(i) as antitumor agents | |
KR101560263B1 (en) | Novel Tetranuclear Arene-Ruthenium Compound and Parmaceutical Composition for Treating or Preventing Cancer Containing the same | |
BR102019011056A2 (en) | COPPER COMPOUNDS (II) WITH N-BINDERS, O-DONORS DERIVED FROM H2SALAN WITH ANTITUMORAL ACTIVITY | |
KR101560262B1 (en) | Novel Ruthenium Heterocycle Compound and Parmaceutical Composition for Treating or Preventing Cancer Containing the same | |
JP2021088511A (en) | Anticancer drug | |
KR101435294B1 (en) | Novel Arene-Ruthenium Compound and Pharmaceutical Composition for Preventing or Treating Cancer Containing Thereof | |
KR101360514B1 (en) | Novel Tetranuclear Arene-Ruthenium Compound and Parmaceutical Composition for Preventing or Treating Cancer Containing Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |